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ABSTRACT OF DISSERTATION 
 
 
POST-TRANSCRIPTIONAL REGULATION OF AFP AND IgM GENES 
 
Gene expression can be regulated at multiple steps once transcription is initiated.  
I have studied two different gene models, the α-Fetoprotein (AFP) and the 
immunoglobulin heavy chain (IgM) genes, to better understand post-transcriptional gene 
regulation mechanisms. The AFP gene is highly expressed during fetal liver 
development and dramatically repressed after birth.  There is a mouse strain-specific 
difference between adult levels of AFP, with BALB/cJ mice expressing 10 to 20-fold 
higher levels compared to other mouse strains. BALB/cJ mice express low levels of 
Zhx2 and thus incompletely repress AFP. Despite differences in steady state AFP 
mRNA levels in the adult liver between Balb/cJ and wild-type mice, transcription rates 
across this gene were similar, indicating a post-transcriptional regulatory mechanism. I 
found accumulated unspliced RNA across multiple AFP introns in wild-type mice where 
mature AFP mRNA levels are low, suggesting overall AFP splicing is inefficient in the 
presence of Zhx2.  The IgM gene is alternative processed to produce two mRNA 
isoforms through a competition between cleavage/polyadenylation (µspA) and splicing 
reactions and the pA/splice RNA expression ratio increases during B cell maturation.  
Cotranscriptional cleavage (CoTC) events, driven by specific cis-acting elements, are 
required downstream of some poly(A) signals to terminate transcription.  In some cases, 
a pause site can produce similar effect.  I explored whether there is a CoTC-like element 
within the IgM gene that may contribute to developmental changes in the mRNA ratio.  In 
both a B cell and plasma cell line there was a gradual decrease in transcripts 
downstream from the µspA signal, suggesting that there is not evidence for a CoTC 
element within the IgM gene. To examine the effect a CoTC element would have on the 
competition between the splice and µspA reactions, we inserted the CoTC sequence of 
the β-globin gene into different locations downstream of the µspA signal. While the β-
globin CoTC element caused cotranscriptional cleavage in all locations, it only affected 
the µspA/splice ratio when located close to the µspA site. This suggests there is a 
position effect of the inserted CoTC element on the competing polyadenylation and 
splicing reactions within the IgM transcripts. 
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CHAPTER I 
 
INTRODUCTION 
 Changes in gene expression are critical for proper cellular differentiation during 
development and cell survival.  It also allows adequate response to different 
environmental conditions.  Gene expression can be modulated at different levels, 
including transcriptional regulation, to produce a functional mRNA.  Transcription of 
protein-encoding-genes is a highly complex process carried out by the RNA polymerase 
II complex (RNAPII) which includes several steps: pre-initiation complex assembly, 
transcription initiation, transcription elongation and transcription termination.  Each of 
these steps are tightly coupled to multiple steps of mRNA maturation (capping, splicing 
and cleavage/polyadenylation), and rigorously regulated to modulate gene expression.  
To better understanding the impact of RNA processing on gene expression, several 
transcriptional steps that are targets for gene regulation will be discussed in this thesis 
using two different gene models:  the alpha-fetoprotein (AFP) gene to study the 
mechanism of post-natal repression mediated by splicing regulation and the 
immunoglobulin M (µ) gene to investigate the effect of co-transcriptional cleavage 
(CoTC) on developmental RNA processing and transcription termination.  The 
introduction will consist of a general overview of transcription by RNAPII and how it is 
coupled to RNA processing followed by specific background information regarding the 
two genes used in this study, the AFP and the mouse µ genes.  
 
CO-TRANSCRIPTIONAL RNA PROCESSING 
 The reactions involved in the maturation of mRNA are now known to often occur 
co-transcriptionally as the RNA is extruded from the actively transcribing RNAPII.  This 
observation has changed the old view of eukaryotic gene expression in which the mRNA 
processing reactions were thought to occur post-transcriptionally, one independent of 
the other.  The new model is more dynamic and integrated, where a cross-talk between 
factors involved in each of these reactions ensure accurate processing in a spatial-
temporal manner which also allows for complex regulation (Bentley, 2005; Kornblihtt et 
al., 2004).  
 Coupling of transcription with RNA processing is mediated by a unique feature of 
the RNAPII, the C-terminal domain (CTD) of its largest subunit, Rbp1.  The CTD 
contains multiple heptapeptide repeats (26 in yeast and 52 in mammals) with the 
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consensus sequence Y1S2P3T4S5P6S7, which is the target of regulatory phosphorylation 
at serines 2, 5 and 7.  The phosphorylation state of the CTD (“CTD code”) is a dynamic 
process that changes as transcription across the gene proceeds, and the CTD is thought 
to act as a landing pad that orchestrates the recruitment of factors involved in 
transcription elongation and mRNA processing.  CTD phosphorylation at Ser5 occurs at 
early stages in transcription and promotes association with capping enzymes and 
promoter release.  In contrast, CTD phosphorylation at Ser2 increases as RNAPII 
progresses through the body of the gene with a maximum peak at the 3’-end, and it is 
correlated with transcription elongation, cleavage and polyadenylation and transcription 
termination (Bentley, 2005; Kornblihtt et al., 2004)   
  During transcription initiation, RNAPII binds to the promoter along with the 
general transcription factors (GTFs) to form the Pre-Initiation Complex (PIC) (Figure 1-1, 
Step 1).  Soon after, CTD phosphorylation at Ser5 by the GTF TFIIH takes place.  
Recruitment of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole sensitivity-inducing 
factor (DSIF) and negative elongation transcription factor (NELF) to the transcription 
complex results in arrest of productive elongation (Figure 1-1, step 2).  This pausing 
allows enough time for recruitment of capping enzymes and assembly of the 
transcription elongation complex (TEC).  Addition of the 5’-cap, a methylated guanosine 
attached through an unusual 5’ to 5’ triphosphate linkage, is stimulated by Ser5 CTD 
phosphorylation and it occurs as the RNA emerges from the RNAPII when it is about 25 
bases long.  The 5’-cap is recognized by the cap binding complex (CBC) that in turn 
protects the nascent transcript from degradation by 5’-3’ exonucleases and enhances 
mRNA translation.  Promoter-proximal pausing is relieved by phosphorylation of the CTD 
Ser2 mediated by positive transcription elongation factor b (pTEFb), which causes 
dissociation of NELF and thus, allows transcription elongation to resume (Figure 1-1, 
step 3) (Bentley, 2002; Bres et al., 2008; Mandal et al., 2004; Proudfoot et al., 2002; 
Sims et al., 2004a). Once the RNAPII complex transitions to productive elongation, it is 
very stable and able to transcribe up to hundreds of kilobases without dissociating from 
the DNA template (Nechaev and Adelman, 2011).  Phosphorylation of CTD at Ser2 also 
serves as platform for binding of factors involved in regulation of transcription elongation, 
RNA processing and termination as described latter.  
 Transcriptional pausing at the promoter-proximal region induced in the early 
transcriptional elongation phase, may serve as an important control for gene regulation 
by at least three different ways (Chiba et al., 2010): First, it may act as rate-limiting step 
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to reduce transcriptional level.  Second, it contributes to the maintenance of a “poised” 
state where specific-gene activation and transcription initiation processes have been 
completed, allowing a rapid response to extracellular signals.  It also may favor an open 
chromatin structure by preventing nucleosome formation and finally, it allows functional 
coupling between transcription and RNA processing ensuring that RNA capping has 
been completed before engaging in a productive elongation (Chiba et al., 2010; Nechaev 
and Adelman, 2011). 
 
SPLICING REGULATION 
 Typical mammalian genes are comprised of multiple short exons (<300 bp) which 
are interrupted by long intervening sequences (introns).  Introns must be removed from 
the primary transcript (pre-mRNA) to generate mRNA by a process known as splicing.  
About 90% of human genes undergo alternative splicing to give rise more than one 
mRNA isoform.  Therefore, alternative splicing is an important mechanism to expand the 
proteomic diversity from a limited number of genes encoded by the genome.  Indeed, 
inclusion/exclusion of alternative exons from a primary transcript may result in mRNAs 
that encode for protein products with different function, subcellular localization or 
catalytic activity, which are important for tissue specific and developmental processes 
(Hu and Fu, 2007; Karni et al., 2007; Luco et al., 2011).  Moreover, it may introduce 
alternative exons or intron retention that results in production of truncated proteins or in 
mRNA that are target for degradation by the nonsense-mediated decay (NMD) pathway  
(Tazi et al., 2009).   
The importance of alternative splicing regulation has been increased because 
mis-regulation of mRNA splicing may be involved in human disease, including cancer. 
Many genes involved in apoptosis are alternative spliced and the different isoforms can 
generate proteins with opposite function. For example, alternative usage of a 5´splice 
site coded within exon 2 of the Bcl-x gene can lead to the synthesis of either the pro-
apoptotic isoform Bcl-xS or the anti-apoptotic isoform Bcl-xL (Mercatante et al., 2001). 
Additionally, the function of several tumor suppressor genes (Brca1 and Mdm2) and 
oncogenes (Kras and Wnt), are also regulated by alternative splicing. Hence, generation 
of splice variants from these genes that encode an inactive tumor suppressor or an 
active oncogene play a role in cancer (Mercatante et al., 2001; Venables, 2004). Others 
genes regulated by alternative splicing include those involved in angiogenesis (VEGF) 
and cell adhesion (CD44) whose splicing pattern changes during tumorigenesis (Zerbe 
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et al., 2004).  Another example is the spinal muscular atrophy (SMA) disorder caused by 
the absence of or mutation in the Survival Motor Neuron 1 (SMN1) gene,  which 
encodes for an essential protein involved in assembly of the spliceosome (Singh et al., 
2004; Sumner, 2006). The SMN2 gene, which differs by a nucleotide within exon 7, fails 
to compensate loss of SMN1 gene, because the nucleotide substitution induces exon 7 
skipping and production of a truncated and unstable protein (Singh et al., 2004).  
Increased SMN expression levels could be achieved either by modulating splicing of the 
SMN2 pre-mRNA, induce stabilization of the SMN protein or SMN1 gene replacement 
(Sumner, 2006).  
  Joining of exons is mediated by the spliceosome which is composed of five 
uridine-rich small nuclear ribonucleoprotein particles (snRNPs) called U1, U2, U4, U5 
and U6, and multiple non-snRNPs splicing factors.  Splicing involves the recognition of 
consensus sequences near the intron-exon boundaries and conserved elements in the 
introns (Figure 1-2A).  The early steps of the spliceosome assembly involve recognition 
of the consensus elements at both ends of the intron to form the early (E) complex: U1 
snRNP binds to the 5´splice site, the branchpoint-binding protein (BBP) binds to the 
branchpoint site, while the heterodimeric U2 snRNP auxiliary factor (U2AF) recognizes 
the polypyrimidine tract and the 3´ AG (Figure 1-2B).  Next, U2 snRNP is recruited to the 
branch site aided by the U2AF which results in the displacement of BBP to form the A 
complex.  The tri-snRNP particle, comprised of U4/U6/U5, then joins the complex, 
bringing together the two splice sites that lead to the B complex.  Once the assembly of 
the spliceosome occurs, there is a dynamic rearrangement of interactions that promotes 
release of U1 and U4 snRNPs.  This results in the formation of the catalytically active 
spliceosome known as C complex which carries out the two trans-esterification reactions 
leading to intron excision (Cartegni et al., 2002; Dou et al., 2006; Sanford et al., 2005; 
Smith and Valcarcel, 2000; Watson, 2004).  Although these conserved sequences are 
required for splicing, they are not sufficient to determine the correct exonic boundaries.  
Regulatory elements such as splicing enhancers and silencers located within either 
exons or introns act in both constitutive and regulated splicing.  These elements called 
exonic or intronic splicing enhancers (ESE/ISE) and exonic or intronic splicing silencers 
(ESS/ISS) consist of short highly degenerate sequences that are generally bound by 
positive or negative trans-acting splicing factors often serine/arginine-rich (SR) proteins 
and heterogeneous nuclear ribonucleoproteins (hnRNP), respectively.  Binding of these 
regulators to their corresponding cis-acting elements favor or inhibit recruitment of early 
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spliceosome components.  This plays an important role in the decision of splice site 
selection that ultimately determines whether an exon will be included or excluded in the 
mRNA (Baralle and Baralle, 2005; Pagani and Baralle, 2004).  Indeed, different tissues 
show not only differences in relative concentration but also a unique pattern of SR 
proteins and hnRNPs.  These differences can affect splice choice in multiple RNAs and 
contribute to cell-specific gene expression (Smith and Valcarcel, 2000; Zahler et al., 
1993). 
 Alternative splicing is not only affected by the relative abundance of different 
splicing factors at the time a gene is expressed.  Extensive experimental evidence 
indicates that the elongation rate, promoter structure, transcription regulators, chromatin 
structure and RNA secondary structure also can affect alternative splicing. 
 A slowed transcriptional elongation rate or increased pausing of the RNAPII led 
to enhanced inclusion of exons with weak splice sites, presumably because it gives 
more time for the recruitment of splicing factors before the downstream competing splice 
site was transcribed (Kornblihtt, 2006; Luco et al., 2011).  This was neatly demonstrated 
by utilizing reporter minigenes containing the exon 33 (E33 or EDI) of the Fibronectin 
(FN) gene and a wild-type or slow mutant of RNAPII.  It was observed that the slow 
mutant RNAPII stimulates inclusion of the E33 by about 3-fold compared to wild-type 
RNAPII (de la Mata et al., 2003; Kornblihtt et al., 2004).  Similarly, pause sites can 
regulate alternative splicing by temporarily arresting or slowing RNAPII.  Insertion of the 
MAZ pause element in the tropomyosin gene, between the splice junction and its 
regulatory element, enhanced inclusion of tropomyosin exon 3 (Luco et al., 2011; 
Roberts et al., 1998) 
 How promoter structure influences alternative splicing was first discovered 
through studies with reporter minigenes containing the alternative exon 33 (E33) of the 
FN gene, driven by different RNAPII promoters.  It was observed that inclusion of the 
E33 exon was about 10 times higher when transcription was driven by the FN or the 
CMV promoters than when it was driven by the weaker α-globin promoter (Cramer et al., 
1999; Cramer et al., 1997; Kornblihtt, 2005, 2006).  The effect of the promoter on 
alternative splicing can be mediated by differences in promoter occupancy by 
transcription factors which then, may impact transcription elongation rates or splicing 
factor recruitment, directly or indirectly.  For example, the thermogenic coactivator PGC-
1, is recruited at promoters with DR-1 elements bound by PPARγ.  PGC-1 in turn recruits 
SRp40, resulting in EDII exon skipping (Kornblihtt, 2005).  
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 Studies with the FN reporter minigene also revealed that chromatin structure can 
impact alternative splicing.  It was observed that increased histone acetylation, induced 
by the histone deacetylation inhibitor trichostatin A, enhanced skipping of the E33 exon 
(Nogues et al., 2002).  Moreover, genome-wide analysis has shown that nucleosomes 
are strikingly enriched on exons as compared to introns, suggesting they may participate 
in the exon definition process (Schwartz et al., 2009).  The average exon size is 140-150 
nt, compared to the nucleosome occupancy of 147 nt of DNA.  In addition, nucleosomes 
are even more prominent in exons with weaker splice sites, suggesting that they may 
regulate alternative splicing.  Furthermore, some histone modifications are specifically 
enriched in exonic nucleosomes compared to their flanking intronic regions; these 
modifications possibly mark the nucleosomes for binding to RNA-processing factors 
(Luco et al., 2011; Perales and Bentley, 2009).  In addition, histone modifications can 
function as docking sites for chromatin binding factors.  A nice example of the correlation 
between histone modifications and alternative splicing was recently reported by Saint-
André et al. (2011).  They demonstrated that H3K9 trimethylation is specifically enriched 
throughout the alternative exons of the CD44 gene. This histone mark functioned as 
binding sites for phosphorylated HP1γ, which mediated the inclusion of CD44 alternative 
exons. They noticed that HP1γ induces accumulation of RNAPII on the alternative exon 
region and therefore suggested a decrease in the transcription elongation rate.  In 
addition, HP1γ also stabilizes association between the nascent RNA with the chromatin 
which may also enhance the inclusion of the CD44 alternative exons (Saint-Andre et al., 
2011). 
 
CO-TRANSCRIPTIONAL SPLICING AND TRANSCRIPTION COUPLING 
 Initial evidence that splicing is co-transcriptional came from analyses of nascent 
transcripts of Drosophila embryo by electron microscopy.  These data visualized 
ribonucleoprotein assembly and intron looping on nascent transcripts occurs still 
attached to RNAPII (Beyer and Osheim, 1988).  A recent analysis of the c-Src and the 
FN pre-mRNAs from chromatin-associated and nucleoplasmic RNA fractions revealed 
that most introns are removed before the transcript is released from the chromatin 
(Pandya-Jones and Black, 2009).  However, introns flanking constitutive exons were 
removed in a 5’-3’ fashion, while introns neighboring alternative exons showed 
differences in excision efficiency, indicating they were not removed in a strict 5’-3’ 
direction, likely allowing for regulation. 
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  This and numerous other studies establish that the splicing machinery is 
recruited and introns are committed to splice co-transcriptionally, indicating that the 
decision of whether an exon will be included or skipped is generally determined before 
the nascent transcript is released.  However, this does not rule out that splicing of some 
introns will occur post-transcriptionally.  Additional evidence that splicing is coupled to 
transcription is the interaction between splicing factors including SR proteins and U1 
snRNP with the RNAPII (Luco et al., 2011).   
 
ALTERNATIVE SPLICING AND THE NONSENSE-MEDIATED DECAY PATHWAY  
 Nonsense-mediated mRNA decay (NMD) is a conserved surveillance pathway 
present in eukaryotes for degradation of transcripts containing premature termination 
codons (PTC). This prevents translation of mRNA that would produce deleterious 
truncated proteins. Indeed, about 30 % of inherited genetic disorders would be 
generated as result of nonsense mutations or frameshifts that introduce nonsense 
codons and degradation of those transcripts by NMD, has been shown to ameliorate the 
disease phenotype. The intriguing conservation of NMD among the eukaryotes has 
suggested other functions for NMD pathway. Bioinformatic analyses point out that about 
10 % of naturally occurring transcripts would produce alternative splice variants 
containing a PTC.  Thi suggests a mechanism that couples alternative splicing with NMD 
to achieve a suitable regulation of gene expression by modulating the stability of target 
transcripts in a given developmental or physiological condition. By means of this 
mechanism, the NMD pathway plays an important role in regulating diverse biological 
processes such as cell proliferation, cell cycle, metabolism, transcription and telomere 
maintenance (Behm-Ansmant and Izaurralde, 2006; Boelz et al., 2006; Frischmeyer and 
Dietz, 1999; Mendell et al., 2004). 
 Activation of the NMD pathway relies on protein complexes deposited 20-24 
nucleotides upstream of exon-exon boundaries.  These multiprotein complexes, referred 
to as exon junction complexes (EJCs), serves as platform for assembly of the NMD 
effectors (Upf1, Upf2 and Upf3) that lead to mRNA degradation when premature 
termination codons are recognized (Behm-Ansmant and Izaurralde, 2006).  A simple 
model of NMD pathway activation is depicted in Figure 1-3. In this model, Upf3 is 
recruited to the mRNA during splicing by interactions with the EJC, while Upf2 may join 
the complex after mRNA export.  During the first round of translation, Upf2, Upf3 and 
other components of the EJC are removed as ribosomes trasverse the mRNA, while 
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stop codons are recognized by the eukaryotic release factors (eRF1 and eRF3).  
Detection of a PTC, which is defined as a stop codon located more than 50 nucleotides 
upstream of an exon-exon junction, will avoid complete removal of downstream Upf 
proteins and therefore, recruitment of Upf1.  This triggers phosphorylation of Upf1 and 
rapid degradation of mRNA by decapping enzymes and 5’-3’ exonucleases (Behm-
Ansmant and Izaurralde, 2006; Chang et al., 2007). 
 
CLEAVAGE/POLYADENYLATION AND TRANSCRIPTION TERMINATION by RNAPII 
 Transcription termination is described as the process by which RNA polymerase 
ceases transcription and releases the nascent RNA and DNA template (Figure 1-1, step 
4).  RNAPII release generally occurs downstream of the poly(A) site, which allows 
polymerase recycling and prevents interference at downstream promoters.  Although 
transcription termination by the RNAPII is not completely understood, it is known that it 
requires a functional poly(A) site and is coupled to 3’-end mRNA processing (Dye and 
Proudfoot, 2001; Gromak et al., 2006).  Poly(A) signals of protein-coding genes contain 
a conserved hexanucleotide sequence, AAUAAA and a G/U-rich or U-rich element 
located 10-50 nucleotides downstream.  The 3’-end processing of most mRNAs is a two-
step reaction involving the cleavage at a CA between the AAUAAA and the G/U-rich 
elements and the addition of about 200 adenosines at the 3’-end of the mRNA (Figure 1-
4A).  The cleavage and polyadenylation machinery includes cleavage and 
polyadenylation specificity factor (CPSF) that binds to the AAUAAA sequence.  It is 
stabilized by binding of cleavage stimulatory factor (CstF) at the G/U-rich element, 
followed by the cleavage factors I and II (CFI/CFII) (Figure 1-B).  Rapid addition of the 
poly(A) tail at the exposed 3’-OH is carried out by the poly(A) polymerase (PAP) and 
thus, the mRNA is stabilized.  The downstream cleavage product, having an uncapped 
5’-end is, instead, highly unstable and rapidly degraded (Bentley, 2005; Gromak et al., 
2006; Perales and Bentley, 2009; Rosonina et al., 2006).  
 Recruitment of 3’-end processing factors start at the promoter of protein-
encoding genes. CPSF is recruited to the pre-initiation complex by the general 
transcription factor TFIID.  Once transcription initiates, CPSF dissociates from TFIID and 
associates with the transcription elongation complex (TEC), presumably by binding to 
the RNAPII body (Dantonel et al., 1997).  The CstF complex, composed of three 
subunits (CstF50, CstF64 and CstF77), assembles during transcription.  This is based 
on the finding that Cst64 localizes close to the transcription start site while CstF77 is 
 9 
detected downstream of the poly(A) signal in MYC, GAPDH and p21 genes (Glover-
Cutter et al., 2008).  CPSF binds to CstF and RNAPII in a mutually exclusive manner. 
This suggests that the formation of a functional CPSF and CstF complex may be 
modulated by transference of CPSF from the RNAPII body to CstF at the CTD, and 
subsequently to the nascent RNA after the poly(A) signal is synthesized (Glover-Cutter 
et al., 2008; Nag et al., 2007; Perales and Bentley, 2009). 
 RNAPII pausing generally occurs within 0.5 and 2 Kb downstream of the poly(A) 
site.  Pausing at the 3’-end of genes correlates with maximal CTD Ser2 phosphorylation 
and high level of 3’-processing factors recruitment.  It is thought that pausing at the 3’-
end coordinates poly(A) site processing and transcription termination by an uncertain 
mechanism.  Indeed, many proteins involved in cleavage/polyadenylation are also 
required for transcriptional termination, such as Pcf11 and Rat1 (Xrn2 in mammals).  
The Pcf11 subunit of CFII is required for both processes.  Beside its role in pre-mRNA 
cleavage, Pcf11 has been suggested to act as a terminator factor by directly binding to 
Ser2 CTD and destabilizing the TEC (Zhang and Gilmour, 2006).  The yeast 5’-3’ RNA 
exonucleases Rat1 is recruited to the CTD during transcription and is implicated to 
promote recruitment of cleavage/polyadenylation factors essential in termination (Luo et 
al., 2006). It also has been suggested that upon 3’-end RNA cleavage, Rat1/Xrn2 is 
responsible for 5’-3’ degradation of the nascent transcript and possibly, aids in the 
RNAPII release (Bentley, 2005; Luo et al., 2006; Rosonina et al., 2006; West et al., 
2004).   
 Some poly(A) signals have the intrinsic ability to pause RNAPII and direct 
transcription termination in model constructs (Orozco et al., 2002).  In these cases, 
termination occurs as a gradual decrease in RNAPII loading over hundreds to thousands 
bases downstream of the poly(A) signal, depending on the poly(A) strength (Orozco et 
al., 2002).  However, additional downstream elements have been reported to increase 
termination efficiency in several genes.  These sequences may be critical for closely 
spaced genes to avoid transcription into promoters of downstream genes.  Such is the 
case of the human complement C2 gene, spaced just 421 bp from the Factor B gene.  It 
was demonstrated that transcription termination in the C2 gene occurs just downstream 
of the poly(A) site, mediated by a 160 bp G-rich sequence that may bind the zinc finger 
protein MAZ.  MAZ binding induced pausing of the RNAPII and additionally, DNA 
bending that may favor disassembling of the TEC (Ashfield et al., 1991; Ashfield et al., 
1994).   
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 Pause sites are also reported to aid in transcription termination, which is the case 
in the human Gγ-globin (Plant et al., 2005) and α2-globin genes (Enriquez-Harris et al., 
1991).  The human Gγ-globin termination element consist of multiple weak pause sites 
and a strong poly(A) signal.  In contrast, the pause site in the α2-globin gene consists of 
a 92 bp long sequence combined with a weaker poly(A) signal.  The α2-globin pause 
site contains a nearly perfect (CAAAA)6 repeat proposed to either form a specific 
structure to the DNA template or binding site for a protein binding to the nascent RNA 
(Enriquez-Harris et al., 1991). 
 More recently, another elment required for efficient termination was identified in 
the 3’ flanking region of the human β-globin gene.  This element is positioned between 
900 and 1600 bp downstream of the poly(A) site and contains the unique ability to 
undergo cotranscriptional cleavage (CoTC) by a poorly understood mechanism (Dye et 
al., 2006; Dye and Proudfoot, 2001; Teixeira et al., 2004).  This element was uncovered 
by performing a run-on assay with nascent transcripts selected using an antisense 
biotinylated RNA probe targeting the poly(A) region (Dye and Proudfoot, 2001).  
Transcripts containing the sequences downstream of the CoTC region were not 
contiguous with the selected RNA, suggesting that they were cleaved.  This was further 
confirmed by reverse transcription followed by PCR (RT-PCR) using primers spanning 
the region downstream of the poly(A) site.  Deletion of the CoTC sequence eliminated 
transcription termination but did not affect 3’-end processing.  The absence of 3’-end 
processing, by mutating the poly(A) signal, also abolished termination but did not affect 
cleavage within the CoTC region.  Therefore, both 3’ end processing and CoTC were 
required for transcription termination (Dye and Proudfoot, 2001).  Gromak et al. (2006) 
also demonstrated that the β-globin CoTC element can be replaced by four tandem MAZ 
pause elements to support transcription termination in a poly(A)-dependent manner in 
this transcripiton unit. 
 Similar to the β-globin CoTC element, sequences undergoing cleavage 
downstream of a poly(A) site have been identified in the ε-globin gene (Dye and 
Proudfoot, 2001) and more recently in the mouse serum albumin gene (MSA) (West et 
al., 2006).  However, they differ from the β-globin CoTC element in various 
characteristics.  The ε-globin termination elements are more diffuse and involve long 
tracts of the 3’ flaking region, which corresponds to differences in transcription 
termination profiles; transcription termination in the β-globin gene occurs abruptly within 
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the 3’ flanking region while transcription termination in the ε-globin gene occurs gradually 
over about 1.65 kb downstream of the poly(A) site (Dye and Proudfoot, 2001).  Unlike 
the MSA CoTC element, the human β-globin CoTC is A/U-rich (West et al., 2006).   
 As decribed above, there is a considerable sequence heterogeneity among the 
termination elements identified, making their existence difficult to predict without a 
functional assay.  But their effect on transcription temination, in all the cases, is 
dependent on a poly(A) signal.   
 The current model of transcription termination postulates that there is a 
cooperative association of Rat1 and cleavage/polyadenylation factors, such as Pcf11, 
with the Ser2 CTD.  When the poly(A) signal is transcribed and recognized by these 
factors, this may induce allosteric changes in the RNAPII, making it prone to termination.  
This may be enhanced by additional sequences that act to pause or slow RNAPII 
transcriptional elongation.  Cleavage of nascent RNA at the poly(A) site or at a CoTC 
element leads to two RNA products; the mRNA is rapidly polyadenylated, while the 3’-
cleavage product which remains attached to the RNAPII is targeted for degradation by 
5’-3’ exonucleases Rat1/Xrn2.  Rat1/Xrn2-induced degradation may aid to release 
RNAPII (Gromak et al., 2006; Luo et al., 2006). 
 As has been discussed, regulation of gene expression is a very complex process 
that involves not only control of transcription initiation, transcription elongation and 
transcription termination, but also it can be modulated at different RNA processing steps.  
For instance, regulation of alternative RNA splicing may lead expression of proteins with 
different functions or subcellular localization, or even mRNAs that differ in stability.  
Better understanding of the mechanism by which genes are tightly regulated may 
generate therapeutic tools that could be used for amelioration of human diseases such 
as spinal muscular atrophy and cancer.  Here, I will discuss two different gene models, 
the AFP and the IgM (µ) genes, that we study to gain insight into mechanisms coupling 
transcription with RNA processing.  First, I will give some background information on 
what is known about the AFP and µ gene regulation. 
 
ALFHA-FETOPROTEIN FUNCTION AND DEVELOPMENTAL GENE EXPRESSION 
 The α-fetoprotein (AFP) gene consists of 15 exons that encode a glycoprotein of 
about 70 KDa with a carbohydrate (glycan) moiety (Mizejewski, 2004; Peterson et al., 
2011).  The AFP gene is member of the serum albumin gene family which consists of 
five members, Albumin (Alb), vitamin D-binding protein (DBP), α-fetoprotein (AFP), α-
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albumin or afamin (α-Alb or Afm) and AFP-related gene (Arg) protein, that all evolved 
from a common ancestor gene by a series of duplication events (Mizejewski, 2011; 
Peterson et al., 2011).  Although AFP function remains poorly understood, it has been 
reported to be involved in the regulation of growth and differentiation during development 
and it binds and transports many ligands including bilirubin, fatty acids, hormones, 
retinoids, steroids, heavy metals, dyes, dioxins and organic drugs (Mizejewski, 2004). 
 AFP is expressed at high levels and secreted by the yolk sac, liver and, to a 
lesser extent, the gastrointestinal tract during fetal development.  After birth AFP 
expression gradually decreases about 104-105-fold and remains at a low basal level 
throughout adult life (Belayew and Tilghman, 1982; Olsson et al., 1977).  However, 
increased serum AFP is associated with liver and germ cell tumors and therefore, is 
used as biomarker for detection of these abnormalities.  In pregnant women, AFP levels 
are also measured using maternal blood or amniotic fluid to screen for neural tube 
defects and Down syndrome (Spear et al., 2006). 
 Much of the work to understand AFP expression and the dramatic decrease in 
AFP expression after birth has been done in mice (Belayew and Tilghman, 1982; Olsson 
et al., 1977).  Early studies to understand the mechanisms of postnatal AFP silencing 
were performed by measuring the serum AFP levels in adult mice of different inbred 
strains.  BALB/cJ mice were found to express up to 20-fold higher serum AFP levels 
compared to other mouse strains.  The post-natal persistence of AFP expression is a 
recessive trait controlled by a gene called raf (regulation of AFP) and later renamed Afr1 
(Alpha-fetoprotein regulator 1) (Olsson et al., 1977).  Subsequently, it was shown that 
the higher levels of AFP in BALB/cJ correlated with higher steady-state liver AFP mRNA 
levels.  AFP expression also is reactivated in adult liver during liver regeneration but this 
induction is controlled by another gene named rif (regulation of induction of AFP) or Afr2 
(Belayew and Tilghman, 1982). 
 Linkage analysis initially mapped the Afr1 gene to mouse chromosome 15 
(Blankenhorn et al., 1988).  Then, performing a positional cloning using a high-resolution 
mapping, Afr1 was identified as the Zinc-fingers and homeoboxes 2 (Zhx2) gene 
(Perincheri et al., 2005).  This analysis revealed that the BALB/cJ Zhx2 allele contains 
an ETnIIα endogenous retroviral element insertion within the intron 1. While normal 
transcription initiation of the Zhx2 gene in BALB/cJ mice occurs, most pre-mRNAs splice 
to the retroviral element and a very low fraction of the mRNA is properly spliced to 
encode full length Zhx2 mRNA.  This hypomorphic mutation dramatically reduces Zhx2 
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expression in BALB/cJ adult mice compared to other mouse strains expressing the wild-
type Zhx2 allele (Perincheri et al., 2008).  Lower Zhx2 expression in adult BALB/cJ mice 
correlates with increased accumulation of liver AFP and H19 mRNA levels, indicating the 
role for Zhx2 in repressing expression of both genes in perinatal liver.  In fact, 
expression of a Zhx2 transgene driven by a liver-specific transthyretin 
enhancer/promoter in BALB/cJ mice led to complete repression of AFP and H19 in adult 
liver, confirming that Zhx2 is responsible for the Afr1 phenotype (Perincheri et al., 2005).  
Moreover, levels of Zhx2 are observed to increase after birth as AFP levels decrease, 
consistent with the role of Zhx2 in AFP repression. 
 The H19 gene was isolated as another target of Zhx2 through a screen for 
murine fetal liver cDNA clones that had decreased expression after birth (Pachnis et al., 
1984).  The H19 gene product is a long non-coding RNA, 2.4 kb in length, which has 
been extensively studied as model of genomic imprinting (Brannan et al., 1990; Pachnis 
et al., 1988).  More recently, the cell-surface proteoglycan 3 (Gpc3), which belong to a 
family of proteins associated with cell growth, development and growth factor responses, 
was also identified to be regulated by Zhx2 (Morford et al., 2007).  Deregulation of Gpc3 
expression has been associated with Simpson-Golabi-Behmel syndrome characterized 
by general overgrowth as well with different types of tumors.  Zhx2 may also control 
many other genes based on recent work in which a quantitative trait locus (QTL) on 
chromosome 15, called Hyperlipidemia 2 (Hyplip2), involved in regulation of cholesterol 
and triglyceride levels, was identified to be Zhx2.  BALB/cJ mice, which express very low 
levels of Zhx2, showed reduced serum cholesterol and triglyceride levels compared to 
other mouse strains.  Additionally, complementation with a Zhx2 transgene resulted in 
increased-serum cholesterol and triglyceride levels as compared to other mouse strains, 
indicating Zhx2 is responsible for this trait.  Comparison of global gene expression 
analysis from livers of BALB/cJ and Zhx2-expressing mice indicated that about a 
thousand genes were differentially expressed, some of which are known to be involved 
in liver function and plasma lipid metabolism.  From this study, Lipoprotein lipase (Lpl) 
was reported as a new target of Zhx2 which showed a similar pattern of developmental 
expression like AFP, H19 and Gpc3.  However, the Ear11 gene, a member of the 
eosinophil-associated ribonuclease family, showed the opposite expression pattern, 
suggesting that Zhx2 function may act in a context-dependent manner (Gargalovic et al., 
2010).  Interestingly, known targets of Zhx2 such as AFP, H19, Gpc3 and Lpl are 
generally elevated in liver tumors (Gargalovic et al., 2010; Spear et al., 2006).  
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ZINC FINGER AND HOMEOBOXES (ZHX) FAMILY 
 The Zinc fingers and homeoboxes (ZHX) family consists of three members, 
ZHX1, ZHX2 and ZHX3.  Human ZHX1 was identified as a NF-YA interacting protein by 
screening a human liver cDNA library using a yeast two-hybrid system (Yamada et al., 
1999).  ZHX1 was independently isolated by immunoscreening of a bone marrow 
stromal cell cDNA library (Barthelemy et al., 1996; Yamada et al., 1999).  Human ZHX2 
and ZHX3 were identified later as ZHX1-interacting proteins by screening rat liver and 
ovarian granulosa cell cDNA libraries using ZHX1-fused to the GAL4-DBD as bait in a 
yeast two-hybrid system.  ZHX proteins are reported to form homodimers and 
heterodimers with each other as well with NF-YA (Kawata et al., 2003a; Kawata et al., 
2003b; Yamada et al., 2003). 
 All ZHX proteins contain two C2H2-type zinc finger domains and 4 (ZHX2 and 
ZHX3) to 5 (ZHX1) homeodomains.  They also share similar gene structure, consisting 
of 4 exons where the proteins are encoded by an unusual long exon (exon 3) with the 
exception of the ZHX3, in which the last 8 nt are encoded by the last exon.  ZHX1 is 
linked to ZHX2 in chromosome 8 (Chromosome 15 in mouse) while ZHX3 is located on 
chromosome 20 (Chromosome 2 in mouse).  Based on the sequence similarities, gene 
structure and phylogenetic analysis of mouse ZHX proteins, it was suggested that ZHX 
genes were originated from a common ancestral gene by two different duplication events 
(Kawata et al., 2003a; Spear et al., 2006).  
 Analysis of tissue distribution of human ZHX mRNAs by Northern blot indicated 
that they are ubiquitously expressed, although transcript levels varied among the tissues 
examined (Kawata et al., 2003b; Yamada et al., 2003; Yamada et al., 1999).  ZHX1 
mRNA showed two major transcripts of 4.5 and 5 kb, Zhx2 is expressed as a single 
transcript of 4.4 kb, while ZHX3 is expressed as multiple mRNAs of 9.4, 7.3, 5.0 and 4.6 
kb.  Similar analysis of Zhx2 mRNA from mouse tissues indicated that a single 4.4 kb 
Zhx2 transcript is also ubiquitously expressed, although levels are lower in liver and in 
testis than the other tissues assayed (Perincheri, 2005).  ZHX genes are also expressed 
in all vertebrates analyzed including human, rodents, dogs and zebrafish but 
homologues are not found in non-vertebrates such as Drosophila, Caenorhabditis 
elegans and yeast, suggesting that ZHX proteins are restricted to the vertebrate lineage 
(Spear et al., 2006). 
 ZHX2 has been called a transcriptional repressor based on a cell culture system 
utilizing a luciferase reporter gene driven by 5 copies of the GAL4-DNA binding domain.  
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Co-transfecting HEK293 cells with a plasmid expressing ZHX2 fused to the GAL4 DNA-
binding domain reduced luciferase activity by a maximum of 25% in a dose-dependent 
manner.  Additionally, ZHX2 was shown to interact with NF-YA in vitro and in vivo, 
suggesting that ZHX2 may regulate genes that are regulated by the NF-Y transcription 
factor.  In this regard, a luciferase reporter gene driven by the promoter region of the 
cdc25C gene responsive to NF-Y was used to co-transfect Drosophila SL2 cells.  Co-
transfection of NF-Y expression plasmids activated luciferase expression in these cells, 
and this expression was reduced about 30% by co-transfection with a ZHX2-expressing 
plasmid in a dose-dependent manner (Kawata et al., 2003b).  Similar assays were 
performed with other promoters responsive to NF-Y in order to determine the repressor 
activity of all three ZHX proteins.  The M2-type pyruvate kinase (MPK) promoter was 
modestly repressed by ZHX1 and ZHX3, the Hexokinase II (HKII) promoter was 
repressed by all ZHX proteins, and the cdc25C promoter was repressed by ZHX2 and 
ZHX3.  These results indicated that members of the ZHX family negatively regulate 
expression of genes stimulated by NF-Y, although with differences in activity and 
specificity (Yamada et al., 2009). 
 The list of physiological functions of Zhx proteins has increased over the recent 
years, and all indicate they have important roles in cell differentiation and in disease.  
Briefly, ZHX proteins are reported to modulate podocyte gene expression during 
development of nephritic syndrome, where down-regulation of ZHX3 preceded 
proteinuria, a frequent complication in primary podocyte disorders (Liu et al., 2006).  In 
another study, it was shown that ZHX2 is specifically expressed in neural progenitor 
cells during cortical neurogenesis.  Its interaction with the cytoplasmic fragment of 
Ephrin-B in the nucleus regulates transcription and subsequent inhibition of cell 
differentiation required for neural progenitor cell maintenance (Wu et al., 2009).  ZHX2 
also was down-regulated in patients with hereditary persistence of fetal hemoglobin 
(HPFH) and δβ-thalasemia.  The genomic region where ZHX2 lies on chromosome 8 is 
associated with a quantitative trait locus that influences the switch from fetal to adult 
hemoglobin, and found to be responsible for HPFH (De Andrade et al., 2010).  Finally, a 
gene expression profile performed to determine potential genes involved in clinical 
behavior of multiple myeloma (MM) indicated that high levels of ZHX2 expression 
correlated with better response and survival after high-dose therapy (Armellini et al., 
2008).  All the examples listed above suggest that ZHX proteins are involved in the 
control of genes that are involved early in development.  
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 Other studies have suggested that ZHX2 is deregulated during liver cancer 
progression.  Lv et al. reported that silencing of ZHX2 by promoter hypermethylation was 
observed in about half of the Hepatocellular Carcinoma (HCC) samples analyzed 
compared to control samples (no tumor).  ZHX2 mRNA levels in these HCC samples 
were inversely correlated with serum levels of AFP (Lv et al., 2006).  However, in 
another report, ZHX2 protein expression was analyzed by immunohistochemistry of 
tissue microarrays from liver tissues obtained from cholangitis, cirrhosis, adjacent non-
tumor tissues, primary HCC tissues and matched metastatic lesions, and found that 
ZHX2 expression was detected only in HCC tissues.  Higher expression of ZHX2 
correlated with HCC clinical stage III and IV compared to stage I and II, and in metastatic 
lesions compared to primary HCC lesions (Hu et al., 2007).  Because these studies 
come to opposite conclusions regarding a potential role for ZHX2 in HCC progression, 
further studies are warranted in this area. 
 
AFP REGULATORY ELEMENTS 
 Regulatory elements that drive mouse AFP expression are contained within a 7.6 
kb DNA region upstream of the AFP transcription start site and include the promoter, a 
repressor and three enhancer elements.  The AFP promoter consists of 250 bp directly 
adjacent to exon 1 and its activity is restricted to the liver.  It contains multiple binding 
sites for liver-enriched and ubiquitous transcription factors including the Hepatocyte 
Nuclear Factor 1 (HNF1), Nuclear Factor 1 (NF1), CAAT/Enhancer binding protein 
(C/EBP), Fetoprotein transcription factor (FTF) and Nkx2.8.  An overlapping site for 
HNF1 and NF1 binding located at -120 from the AFP transcription start site has been 
reported to contribute to the promoter activity (Feuerman et al., 1989; Spear, 1999).  In 
fact, it has been reported that a single nucleotide substitution in human at two different 
HNF1 binding sites within the AFP promoter (-60 and -120) are associated with 
hereditary persistence of AFP (Alj et al., 2004; Blesa et al., 2003).  More recently it was 
reported that the Zinc finger and BTB domain containing 20 (ZBTB20) is involved in 
transcriptional repression of AFP in perinatal liver by binding to the region between -108 
and -53  of the mouse the AFP promoter (Xie et al., 2008). 
 A repressor region located between the -250 and -838 bp region was reported to 
be required for postnatal AFP repression, since an AFP transgene lacking  this region 
continued to be expressed in adult liver (Vacher and Tilghman, 1990).  Additional 
binding sites for Foxa and p53 family members, p53 and p73, are located around the -
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850 bp region.  Interference of Foxa binding at this site by p53 is suggested to contribute 
to post-natal AFP repression (Peterson et al., 2011; Xie et al., 2008).  However, in other 
studies, the 250 bp promoter without this repressor region was sufficient to repress a 
heterologous reporter gene in transgenic mice (Peyton et al., 2000a) 
 The three enhancers, referred to as E1, E2 and E3, are positioned at about -2.5, 
-5.0 and -6.5 kb, respectively, and are each about 200-300 bp (Godbout and Tilghman, 
1988).  E1 and E2 enhancers showed higher similarity suggesting they arose from a 
duplication event; moreover, E1 is present in rodent but it is absent in other species 
analyzed (Long et al., 2004).  Studies in transgenic mice indicated that the three 
enhancers are active in both fetal and adult mouse livers (Ramesh et al., 1995).  In the 
adult liver, E1 and E2 are active in all hepatocytes while E3 is active only in hepatocytes 
around the central vein due to continuous repression of this enhancer in non-pericentral 
hepatocytes (Peyton et al., 2000b).   
 
REGULATION OF AFP POST-NATAL REPRESSION BY ZHX2 
 The AFP cis-acting elements required for Zhx2 responsiveness have been 
studied using mouse models.  Although the cis-acting elements required for 
transcriptional activation of AFP expression, such as the enhancer and promoter 
regions, have been well characterized in cultured cells, the developmental silencing 
observed in vivo has not been reproduced in these in vitro systems.  The BALB/cJ 
mouse strain, containing the Zhx2 mutation that results in incomplete post-natal AFP 
repression has been an important tool for studying this process.  Because the mouse 
AFP gene consists of 15 exons and is about 22 kb, the use of AFP minigenes allows 
ease of manipulation for deletion and mutation of sequences that may impact AFP 
regulation.  Minigenes also can be distinguished from the endogenous AFP gene for 
measuring gene expression.  To study Zhx2-mediated regulation, transgenic mice 
expressing AFP minigenes were generated in a mouse strain expressing Zhx2 and 
backcrossed twice to BALB/cJ.  F2 offspring were genotyped to screen for transgenic 
mice heterozygous or homozygous for the recessive Zhx2 mutant allele.  Initial studies in 
cultured cells and transgenic mice utilized an AFP minigene that consisted of the two 
first and three last exons linked to the 7.6 kb 5’-flanking region of AFP gene.  This 
minigene was developmentally regulated and expressed in the same tissue-restricted 
manner as the endogenous AFP gene (Krumlauf et al., 1985).   
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 Chimeric transgenes, in which the repressor/promoter regions and the five-exon 
AFP minigene were linked to the Albumin enhancer, were regulated by Zhx2 whereas 
transgenes containing the Albumin promoter and Albumin minigene linked to the AFP 
enhancers were not.  These results indicated that AFP enhancers do not direct AFP 
post-natal repression mediated by Zhx2 and, rather, elements contained within the 1 kb 
5’-flanking region or within AFP structural gene were required (Camper and Tilghman, 
1989).  To explore whether sequences within the AFP structural gene are required for 
Zhx2 regulation, transgenic mice expressing the AFP 5’-flanking region containing the 
E1 and the repressor/promoter regions linked to the mouse major histocompatibility 
complex (MHC) class I H-2Dd (AFP-Dd),  were generated.  It was found that the 
unrelated gene linked to AFP 5’-flanking region was expressed in the same tissues and 
postnatally repressed like the endogenous AFP (Spear, 1994).  Moreover, a similar 
chimeric construct in which the Dd gene was linked to the 250 bp AFP promoter and E2 
enhancer was not only postnatally repressed but was also responsive to Zhx2 in a 
similar manner to endogenous AFP.  This indicated that the AFP promoter is sufficient 
for conferring Zhx2 regulation (Peyton et al., 2000b). 
 The studies described above indicated that Zhx2 regulates AFP and H19 genes 
through the promoter.  However, nuclear run on assays showed that the transcription 
rates of H19 gene and AFP transgene were similar between mice that did or did not 
express Zhx2.  Thus, transcriptional difference can not account for the 10 to 20-fold 
difference in adult liver H19 and AFP mRNAs levels.  Therefore, Zhx2 was proposed to 
regulate target genes at the post-transcriptional level (Vacher et al., 1992).  A more 
detailed nuclear run-on experiment was performed in our lab using single strand probes 
derived from M13 clones.  These probes covered the 5’-end, middle and 3’-end of the 
mouse AFP and H19 genes in the sense and anti-sense orientations.  Similar 
transcription rates were observed for both genes in the presence or absence of Zhx2.  
Low levels of antisense transcription were detected, but it was not different between 
mice and does not contribute to Zhx2 regulation.  Also, there was no significant loss of 
signal between the 5’-end probe and 3’-end probes that would indicate early termination 
of transcription.  These result confirmed the post-transcriptional regulation of AFP and 
H19 genes and additionally, demonstrated that neither anti-sense transcription nor 
transcription termination are involved in Zhx2 regulation.  Based on data described 
above, it is proposed that Zhx2 controls target genes by a mechanism that couples 
transcriptional and post-transcriptional steps of gene expression.  It is well documented 
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using artificially constructed minigenes that promoters influence transcription elongation 
and regulate post-transcriptional events such as splicing.  Zhx2 regulation of AFP and 
H19 may be a natural example of where these events interact to regulate endogenous 
gene expression.  
 More recently, the effect of ZHX2 on AFP expression was studied in human 
hepatoma cell lines.  HepG2 and HepG2215 cell lines express low levels of ZHX2 
mRNA which correlated with high level of secreted AFP, while SMMC771 and LO2 cell 
lines express higher levels of ZHX2 mRNA and lower level of secreted AFP.  
Overexpression of ZHX2 in HepG2 cells reduced AFP protein levels in a dose-
dependent manner by about 25%, whereas, down-regulation of ZHX2 by siRNA in 
SMMC771 and LO2 cell lines increased levels of AFP about two-fold without affecting 
Albumin levels.  These results suggested AFP secretion in different hepatoma cell lines 
is inversely correlated with expression of ZHX2.  Additionally, HepG2 cells were co-
transfected with a ZHX2-expressing plasmid and a reporter construct in which the 
luciferase gene was linked to the 269 bp human AFP promoter.  Luciferase activity was 
reduced by about two-fold upon increased expression of ZHX2.  This indicated that 
ZHX2 can also repress AFP expression mediated by the AFP promoter in HepG2 cells 
(Shen et al., 2008).  Similar results were observed with the mouse AFP promoter linked 
to luciferase (Yamada, 2009).  Both cell culture and transgenic mice have provided 
insight into the AFP cis-acting sequences and factors required for expression and 
developmental silencing.  However, it is important to note that in cell culture systems the 
repression of AFP observed is, in most cases, only two-fold, while in the mouse model, 
the presence or absence of Zhx2 results in about 10 to 20-fold difference in AFP 
expression.  More research must be done to improve the cell culture system to study 
AFP regulation by Zhx2 and thus, the mouse model remains an essential tool for 
studying developmental repression by Zhx2. 
 
B CELL DEVELOPMENT 
 B lymphocytes derive from a common lymphoid progenitor cell in the bone 
marrow, where resident stromal cells provide the chemokines and cytokines as well 
intercellular contact required for survival and proper early stage development of B cells.  
This involves productive DNA arrangements of the VHDHJH segments of the 
immunoglobulin (Ig) heavy chain locus and the VLJL segments of the κ or λ light chain 
loci, allowing the expression of a functional B cell receptor (BCR) complex on the B cell 
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surface.  The Ig receptor consists of two identical heavy chains and two identical light 
chains held together through disulfide bonds to form a membrane-bound IgM (µm), and 
together with the Igα and Igβ heterodimer on the B cell surface, delivers intracellular 
signaling important for survival and proliferation.  Once the IgM is expressed on the B 
cell surface, the immature B cells are selected for central tolerance, so B cells that 
recognize self-antigens are removed by apoptosis or undergo further light chain 
rearrangements, mediated by receptor editing, to reduce potential auto-reactivity.  
Immature B cells start to express new adhesion molecules and homing receptors, 
becoming a transitional type 1 B cell (T1 B cell).  This allows transition of the developing 
B cell to the periarteriolar lymphoid sheath in the spleen where local production of B cell 
lymphocyte activating factor induces survival and transition to a T2 B cell.  At this stage, 
B cells migrate to other secondary lymphoid tissues where they become mature naïve B 
cells and co-express IgM and IgD on their surface.  These B cells are ready to encounter  
antigen which will trigger clonal expansion and the differentiation of the B cell into an Ig-
secreting plasma cell (Kurosaki et al., 2010).  
 Upon encounter with antigen, B cells can also undergo isotype switching, a 
process in which expression of IgM and IgD switch to other Ig classes, IgA, IgG or IgE, 
without a change in the antigenic specificity.  Isotype switching is regulated by external 
signals such as cytokines released by T lymphocytes and it involves irreversible 
nonhomologous DNA recombination guided by stretches of repetitive DNA sequences 
known as switch regions (SH).  The SH regions lie in the intron between the JH gene 
segments and the Cµ gene, and upstream of the genes for each other heavy chain 
isotype with the exception of the Cδ  gene.  Unlike IgA, IgG and IgE, co-expression of 
IgD along with IgM does not involve DNA rearrangement, instead it involves alternative 
splicing of the variable region (VHDHJH) to the Cδ1 exon, resulting in the removal of the 
Cµ region in the pre-mRNA (Janeway, 2005; Peterson, 1994b; Peterson, 2007). 
 Ig heavy chain genes encoding IgM, IgD, IgA, IgG and IgE, have similar gene 
structure.  They all encode both membrane-bound and secreted Ig isoforms and 
therefore, undergo regulated RNA processing at the 3’ end of the transcript as B cells 
mature to plasma cells.  In naïve B cells and memory B cells, mRNA encoding the 
membrane-associated isoform predominates, while in plasma cells, the mRNA encoding 
the secreted form is preferentially expressed.  The exclusive expression of the Ig on the 
B cell surface, and Ig secretion in plasma cells, is due in part to differences in the 
relative expression of the mRNA isoforms but also, to the contribution of additional post-
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translational mechanisms, such as differential intracellular retention and protein 
degradation (Peterson, 1994b; Peterson, 2007; Peterson, 2011).  
 
REGULATION OF IgM EXPRESSION 
 The shift between the membrane-associated (µm) and the secreted (µs) IgM 
isoforms observed as B cells differentiate into plasma cells occurs by alternative RNA 
processing at the 3’ end of a common precursor RNA (Figure 1-5).  The µs mRNA is 
produced by cleavage and polyadenylation of the transcript at the proximal (µs) poly(A) 
site, while the µm mRNA is produced by splicing between the Cµ4 and M1 exons 
followed by cleavage and polyadenylation at the distal (µm) poly(A) site.  B cell lines 
express roughly similar levels of µs and µm mRNA while plasma cell lines express 10-20 
fold more µs mRNA than µm mRNA, so the µs/µm mRNA ratio increases as B cells 
progress to plasma cells (Peterson, 2007). 
 The IgM gene has been extensively studied as a model to better understand the 
mechanisms involved in the regulated RNA processing observed during B cell 
development.  For this purpose, plasmids expressing intact or modified sequences of the 
mouse Cµ gene driven by a heterologous promoter have been transiently or stably 
transfected into suitable mouse B cell and plasma cell lines, such as M12 and S194, 
respectively (Peterson, 2007; Peterson, 2011).  The murine B cell line, M12, does not 
express endogenous immunoglobulin, while the murine plasmacytoma cell line S194, 
expresses only the endogenous IgA gene.  The absence of endogenous IgM expression 
in these cell lines make them ideal for expression of transfected IgM constructs (Kim et 
al., 1979; Hyman et al., 1972).  Additionally, when either the wild-type or chimeric IgM 
genes are transfected into B cells and plasma cells, the shift in the µs/µm mRNA ratio, 
from 1-2 to >10, resembles that observed in the endogenous µ gene when resting B 
cells are stimulated into Ig-secreting cells.  These results validate this experimental 
system and it has been a valuable tool for understanding the elements required for the 
regulated shift in the µs/µm mRNA ratio observed during B cell differentiation to plasma 
cells, and it is extensively used in the present study (Peterson, 2007). 
 Based on deletion, substitution and mutations of other portions of the µ gene 
using the approach mentioned above, it was concluded that the strength of the two 
competing reactions, the cleavage and polyadenylation at the µs poly(A) site and the 
Cµ4-M1 splice, has to be balanced in order for regulation to occur.  In the wild-type IgM 
gene both the µs poly(A) site and the splice site are suboptimal.  Substitution of the µs 
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poly(A) site by a stronger poly(A) site and maintaining the suboptimal Cµ4 5’ splice site 
predominantly favored µs mRNA in both B cell and plasma cells, thus the regulation was 
disrupted.  Substitution of the Cµ4 5’ splice site by a consensus splice signal while 
maintaining the suboptimal µs poly(A) site exclusively favored the production of µm 
mRNA, even in plasma cells.  Only when both sequences were replaced with strong 
signals was the µs/µm mRNA ratio developmentally regulated (Peterson, 1992; Peterson 
and Perry, 1989). 
 Deletion of a 158 bp NotI-HindIII fragment 50 bp downstream of the µs poly(A) 
site decreased the µs/µm mRNA ratio by 3- to 8-fold in B, plasma and non-lymphoid 
cells (Peterson et al., 2002).  A detailed analysis of the region uncovered the existence 
of an RNAPII pause site, with the following features:  the fragment enhanced the use of 
a weaker upstream poly(A) site when placed between tandem poly(A) sites;  it could be 
replaced by other known pause sites such as the H3.3 and the MAZ elements and run-
on assays showed an increase in RNAPII loading about 50 bp downstream of the µs 
poly(A) site even when the µs poly(A) was inactivated (Peterson et al., 2002).  
Additionally, the µ pause site effect on µs poly(A) site use was lost when it is moved over 
100 bp downstream from its original position, although it still induced RNAPII pausing 
(Burnside et al., 2011; Peterson et al., 2002).   
 Other parameters that impact the µs/µm mRNA ratio, without affecting the 
developmental regulation between B cells and plasma cells, are the Cµ4-M1 intron size 
(Peterson and Perry, 1986; Tsurushita and Korn, 1987) and the Cµ4 exon size (Peterson 
et al., 1994).  Shortening either Cµ4-M1 intron or the Cµ4 exon favored the splicing 
reaction so more µm mRNA was made.  Deletion and substitution of different portions of 
the µ gene also revealed that there are no gene-specific sequences required for the 
regulated µs/µm mRNA ratio shift between B cells and plasma cells.  Moreover, non-
immunoglobulin genes (β-globin and Major Histocompatibility Complex H-2Dd) that were 
modified by inserting a intronic poly(A) signal, so they could be alternative spliced or 
cleaved and polyadenylated at the inserted poly(A) site, were regulated in B cell and 
plasma cells like the Ig genes (Peterson, 1994a; Peterson, 2011).  This was further 
tested in resting and stimulated B lymphocytes derived from transgenic mice expressing 
the modified Dd gene.  Similarly to the endogenous µ gene, the pA/spliced Dd mRNA 
ratio increased as the B lymphocytes were differentiated (Peterson, 2011; Seipelt et al., 
1998). 
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 These studies indicate that the balanced efficiencies of the competing splice and 
cleavage-polyadenylation reactions are critical features for the developmental Ig RNA 
processing, and the Cµ4-M1 intron and Cµ4 exon sizes have an effect on the efficiency 
of these competing reactions.  Consistent with these facts, other immunoglobulin genes 
that undergo developmental expression regulation have similar gene structures, where 
poly(A) strength and the intron and exon sizes are well conserved (Peterson, 2011). 
 Because the Ig gene structure rather than specific sequences are important for 
regulation, it is likely that the trans-acting factors that regulate the alternative RNA 
processing reactions will be involved in regulating the general splicing and/or cleavage-
polyadenylation reactions.  In fact, there is evidence that both splicing and 
cleavage/polyadenylation activities are different between B cells and plasma cells.  To 
test whether differences in splicing environment alter µs/splice mRNA ratio, µ gene 
constructs were transiently co-transfected with different SR-encoding plasmids in B cell 
(M12) and plasma cell (S194) lines. Expression of several SR proteins, SF2/ASF, 
SRp30c and SRp55, decreased the µs/splice mRNA ratio, suggesting they enhance the 
Cµ4-M1 splice reaction (Bruce et al., 2003).  On the other hand, differences in cleavage 
and polyadenylation activity were also observed when constructs with tandem poly(A) 
sites were expressed in B cell and plasma cell lines.  It is also reported that cleavage 
and polyadenylation efficiency increases as B cell differentiate to plasma cells (Peterson 
et al., 1991).  Therefore, several trans-acting factors involved in either splicing or 
cleavage and polyadenylation may be implicated in the µ RNA processing switch.  Some 
candidates which relative levels differ between B cells and plasma cells have been 
studied, Cst64, hnRNP H/H’/F family and U1 snRNP, however their roles in regulating 
the µs/splice mRNA ratio are not fully understood (Peterson, 2007; Peterson, 2011).  
More recently, the elongation factor ELL2 was reported to be an important factor in 
shifting the Ig heavy-chain (IgH) pre-mRNA processing from the membrane associated 
form to the secreted mRNA form (Martincic et al., 2009).  ELL2, which increases during 
B cell differentiation to plasma cells was shown to bind to the IgH promoter and favor the 
recruitment of Cst64 to the RNAPII near the 5’ end of the gene.  ELL2 expression was 
associated with enhanced polyadenylation at the promoter proximal poly(A) site in a 
construct with tandem poly(A) sites and also increased exon skipping of the Ed1 splicing 
reporter gene.  Therefore, it was suggested that ELL2 influences the IgH pre-mRNA 
processing by increasing the polyadenylation at the promoter-proximal poly(A) site and 
reducing the efficiency of splicing (exon skipping). 
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IgM TRANSCRIPTION TERMINATION  
 Several studies have investigated the transcription termination profiles in the µ-δ 
locus by nuclear run-on analysis, using either resting and stimulated B cells or cells lines 
that represent different B cell developmental stages.  These studies have shown the 
transcription unit is gradually foreshortened as B cells progress to plasma cells.  In IgM 
secreting cells, transcription is terminated predominantly downstream of the µm poly(A), 
while in surface-IgM expressing cells, transcription proceeds throughout the δ locus.  
The gradual foreshortening of transcription termination through the µ-δ locus observed in 
plasma cells, is responsible for the lack of IgD expression.  However, it is not likely to be 
involved in the increased expression of µs mRNA because most transcripts contain the 
Cµ4-M1 splice and thus are able to produce µm mRNA.  Based on the fact that a 
functional poly(A) site is required for efficient transcription termination to occur, the 
earlier transcription termination observed in plasma cells may be explained by a 
developmental increase in efficiency of the µs poly(A) usage (Kelley and Perry, 1986; 
Peterson, 2007; Weiss et al., 1989; Yuan and Tucker, 1984). 
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Figure 1-1. Transcription coupling with RNA processing.  Transcription is a step-wise 
process (black print) in which each step is tightly associated with different RNA 
processing stage (blue print) as described.  Checkpoints at each step (red print) ensure 
proper transcriptional regulation and RNA processing.  Additional detail is explained in 
the text.  
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Figure 1-2. Spliceosome assembly.  (A) Consensus sequences at the intron-exon 
boundaries. (B)  Steps involved in spliceosome assembly. 
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Figure 1-3. Simplified model of the nonsense mediated decay pathway activation. 
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Figure 1-4. Cleavage and polyadenylation process.  (A) Cleavage and polyadenylation 
scheme.  (B) Sequences involved in cleavage and polyadenylation factor recognition. 
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Figure 1-5. IgM gene structure and alternative RNA processing. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
PLASMID CONSTRUCTION 
 pGEM-T-CoTC was made by cloning the β-globin CoTC element into the pGEM-
T easy vector (Promega).  The full β-globin CoTC fragment was PCR-amplified with 
Asp718 ends from β∆5-7p(A)mut (Dye and Proudfoot, 2001) using the primers CoTC-
Fc/CoTC-R800.  The 800bp-PCR product was DpnI-treated and cloned into pGEM-T 
Easy vector following manufacturer instructions. 
 Cµ/CoTC(+), Cµ/CoTC(-), ∆NH/CoTC(+), ∆NH/CoTC(-), ∆AR/CoTC(+) and 
∆AR/CoTC(-) (Table 2-1) were made to determine the effect of having a CoTC element 
at the KpnI site within the Cµ4-M1 intron on the µm/µs mRNA expression ratio.  The 800 
bp Asp718-digested fragment from pGEM-T-CoTC was cloned into IgCµ(WT), 
IgCµ(∆NH) and Cµ(∆AR), that had been digested with Asp718 and treated with SAP, to 
obtain Cµ/CoTC, ∆NH/CoTC and ∆AR/CoTC, respectively.  Cµ(WT) refers to the wild-
type µ construct; Cµ(∆NH) has a 158 bp deletion between the NotI and HindIII sites 
within the Cµ4-M1 intron which contains a RNAPII pause site element (Peterson et al., 
2002); and Cµ(∆AR) contains a 797 bp deletion between the AccI and EcoRV sites in 
the middle of the Cµ4-M1 intron (Peterson and Perry, 1986).  For each construct, clones 
containing the CoTC sequence in either orientation were selected, denoted as (+) when 
β-globin CoTC is in 5´-3´orientation and (-) when the β-globin CoTC is in 3´-5´orientation, 
to obtain Cµ/CoTC(+), Cµ/CoTC(-), ∆NH/CoTC(+), ∆NH/CoTC(-), ∆AR/CoTC(+) and 
∆AR/CoTC(-). 
 Cµ/CoTC(+)-H and ∆NH/CoTC(+)-H (Table 2-1) were made to determine the 
effect of having a CoTC element at the HindIII site on the µm/µs mRNA expression ratio 
in presence or absence of the RNAPII pause site element.  Cloning the β-globin CoTC at 
the HindIII or NotI-HindIII (referred as ∆NH) sites of Cµ required three sequential cloning 
steps.  The 800 bp Asp718-digested fragment from pGEM-T/CoTC was Klenow treated 
to make blunt ends and inserted at either the HindIII or NotI-HindIII sites of pUCPst, also 
Klenow-treated after restriction enzyme digestion. pUCPst contains the 2318 bp-PstI 
fragment of µ gene spanning the region between the Cµ4 and M2 exons cloned into 
pUC9 (Peterson and Perry, 1989).  The ApaI-KpnI fragment containing the modified 
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sequences was cloned into the ApaI-KpnI-cut pSV2Cµ which contains the 6 Kb BglII 
fragment comprising the µ constant region (Peterson and Perry, 1986).  The last cloning 
step transferred the BamHI-BglII fragment of the modified pSV2Cµ into the BamHI-cut 
pIgCµ where an intact µ gene containing the modification could be expressed stably in 
lymphoid cell lines such as M12 and S194 cells (Peterson and Perry, 1989).  
 Cµ/rpI900-H and ∆NH/rpI900-H (Table 2-1) were made to use as intron size 
controls by inserting an unrelated sequence with no known CoTC activity, into Cµ.  The 
rpI900 fragment is a 900-bp BamHI-SmaI fragment from the second intron of the S16 
ribosomal protein gene.  This fragment was Klenow-treated to make blunt ends and 
inserted into the HindIII or HindIII-NotI sites of the µ gene, following the thee-step cloning 
procedure described above.  
 Other plasmid constructs described in previous studies also were used as 
controls. These constructs differ in the Cµ4-M1 intron length by deleting or inserting 
unrelated sequences (Table 2-1).  The ∆NR contains a 351 bp deletion between the 
NcoI and EcoRV sites, ∆AN has a deletion of 446 bp between AccI and NcoI sites, 
AR/rpI900 has 797 bp deleted between the AccI and EcoRV sites and the rpI900 
fragment inserted at the KpnI site, Cµ/rpI900 has the rpI900 fragment inserted at the 
KpnI site in the wild-type Cµ gene (Peterson and Perry, 1986). 
 
CELL LINES AND CULTURE CONDITIONS 
B Cells: 
 M12 murine B cells, a lymphoma-derived cell line deficient in IgM expression 
when established in culture (Kim et al., 1979), were grown in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 50 U/ml 
penicillin/Streptomycin and 50 µM β-mercaptoethanol.  The 38C-13 cell line is derived 
from a C3H/eB mouse-B cell lymphoma and expresses roughly similar amount of µm 
and µs mRNA (Nelson et al., 1983).  This cell line was grown in the same medium as 
M12 cells. 
 
Plasma Cell lines 
 The S194 murine plasmacytoma cell line, a myeloid-derived cell line expressing 
IgA but defective in IgA secretion (Hyman et al., 1972), was obtained from the American 
Type Culture Collection.  S194 cells were maintained in Dulbelcco´s modified Eagles 
medium (DMEM) supplemented with 10% heat-inactivated horse serum and 50 U/ml 
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penicillin/Streptomycin.  The D2 cell line is a 38C-13-derived hybridoma cell line actively 
secreting IgM (µs mRNA >> µm mRNA) (Nelson et al., 1983) and was propaged in RPMI 
1640 medium supplemented with 20% fetal bovine serum. 
 
HEK293 cells 
 HEK293 cells were obtained from the American Type Culture Collection and 
maintained in Dulbelcco´s modified Eagles medium (DMEM) supplemented with 10% 
heat-inactivated fetal bovine serum and 50 U/ml penicillin/streptomycin. 
 
DNA PREPARATIONS, PRIMERS AND SEQUENCING 
 Plasmid DNA used for sequencing or transfections was prepared by cesium 
chloride protocol as described by Ausubel et al. (1987). DNA concentration was 
quantified by optical density at 260 nm.  Primers were purchased from Integrated DNA 
Technologies, Inc. (IDT; Coraville, IA).  DNA sequencing was performed by MWG 
Biotech (High Point, NC) for sequencing. 
 
DNA TRANSFECTIONS 
Stable transfections 
 M12 B cells and S194 plasma cells were stably transfected by electroporation as 
described by Bruce et al. (2003).  About 20 µg of PvuI-linearized plasmid DNA were 
used for transfecting 5x106 cells that had been washed and resuspended in 0.8 ml of 
Opti-MEM-I+GlutaMAX-I (GIBCO).  Cells were electroporated at 250 volts and a 
capacitance of 960 (BioRad) and allowed to recover overnight before being selected with 
G418 at 300 µg/ml for M12 and 600 µg/ml for S194.  Cells were collected after at least 
2-3 weeks of G418 selection and RNA was extracted. 
 
Calcium phosphate transient transfections 
 HEK293 cells were transiently transfected by the calcium phosphate protocol 
described by Spear and Tilghman (Spear and Tilghman, 1990).  Briefly, two 80% 
confluent plates of cells were split into 6 plates the day before transfection. 15 µg of 
plasmid DNA resuspended in 450 µl of 250 mM CaCl2 were added dropwise with slow 
bubbling to 500 µl of 2X HBS (280mM NaCl, 50 mM HEPES, 1.5 mM NaPO4, pH 7.1).  
The precipitate was allowed to sit for 30 minutes at room temperature and then added to 
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a plate of HEK293 cells. After 6 hours, the cells were rinsed and incubated with fresh 
media for 48 hours before being collected for nuclear extract preparation.  
 
RNA PREPARATIONS 
Total RNA extraction 
 Total RNA from 1×107 stably transfected M12 B cells or S194 plasma cells was 
extracted with Trizol reagent following manufacturer instructions (Invitrogen).  Total RNA 
from mouse liver was obtained by homogenization of about 100 mg of liver sample 
followed by two sequential Trizol reagent extractions.  The RNA concentration was 
quantified by optical density at 260 nm.   
 
Nuclear RNA extraction from B cells and plasma cells 
 Nuclear RNA from 38C-13 and D2 cells was isolated by the hot phenol method 
from citric acid-purified nuclei (Schibler et al., 1975).  Briefly, 1-2 ×108 cells were 
resuspended in 10 ml of cold 5% citric acid, homogenized and then centrifuged over 10 
ml of 30% sucrose/5% citric acid cushion at 1000×g for 10 minutes at 4°C.  The pellet 
was resuspended in 10 ml of cold 10mM sodium acetate/10 mM NaCl and centrifuged at 
2000 rpm for 5 minutes.  The pellet was resuspended in 1 ml of 50 mM sodium acetate 
and RNA was extracted by the hot phenol method.  Briefly, 10 ml of 50 mM sodium 
acetate/1% SDS was added while gently vortexing the sample. The suspension was 
extracted with an equal volume of hot phenol saturated with 50 mM sodium acetate, 
incubated for 15 minutes at 68°C with intermittent shaking and then chilled on ice for at 
least 5 minutes. After centrifugation, a second extraction was performed, followed by a 
final extraction with chloroform:isoamylic alcohol (24:1).  RNA was precipitated with 1/10 
volume of 3 M sodium acetate and 2.5 volumes of ethanol.  For RT-PCR analysis, 100-
200 µg of nuclear RNA was further treated with Trizol reagent in order to eliminate 
remnant DNA contamination. 
 
Cellular RNA fractions from mouse liver 
 Mouse liver was homogenized in 10 ml of Buffer I (0.25 M sucrose, 60 mM KCl, 
15 mM NaCl, 15 mM Hepes pH7.4, 2 mM EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5 
mM spermidine and 14 mM β-mercaptoethanol) in a Dounce homogenizer using 18 
strokes with pestle A and 18 strokes with pestle B.  Homogenate was layered on 10 ml 
of Buffer II (same as buffer I but containing 0.75 M sucrose) and spun at 1000 ×g for 10 
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minutes at 4 ºC.  Cytoplasmic fraction corresponding to the pinkish top faction was 
saved for cytoplasmic RNA extraction, while the interface phase was discarded.  The 
nuclear pellet was resuspended in 3.2 ml of Buffer III (same as buffer I but containing 2 
M sucrose) and layered over 1 ml cushion of Buffer III, then spun at 33000 rpm for 1 h at 
4 ºC in a Beckman Coulter “Optima” ultracentrifuge (SW55 Ti rotor) for nuclei 
purification.  Chromatin-soluble and chromatin-insoluble fractions were obtained from 
purified nuclei as described by Pandya-Jones and Black (Pandya-Jones and Black, 
2009).  Briefly, nuclei were resuspended in 400 µl of glycerol buffer (20 mM Tris pH 7.9, 
75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 50% glycerol and proteinase inhibitors) and 
400 µl of urea lysis buffer (20 mM HEPES pH7.6, 1 mM DTT, 7.5 mM MgCl2, 0.2 mM 
EDTA, 0.3M NaCl, 1M Urea, 1% NP-40) was added, mixed and incubated for 10 
minutes on ice.  The nuclear soluble fraction is recovered from the supernatant by 
centrifugation at 14000 rpm in a microcentrifuge for 3 minutes at 4ºC, and used for RNA 
extraction.  The insoluble pellet was washed with 400 µl 1X PBS/1mM EDTA and 
resuspended in 100 µl DNase buffer containing 10 U of RNase-free DNase (Promega).  
After 5 minutes at 37ºC, RNA was extracted with Trizol reagent with following 
modifications:  the DNase-treated insoluble fraction was incubated with Trizol reagent at 
50ºC for about 5 minutes, 200 µl of chloroform was added and the samples were 
centrifuged 15 minutes at 11500 rpm in a microcentrifuge.  The supernatant was 
transferred to a new tube and extracted with phenol/chloroform and ethanol precipitated.  
Cytoplasmic and nuclear soluble fractions were treated with proteinase K prior to RNA 
extraction with Trizol as described for the nuclear insoluble RNA fraction. 
 
Cytoplasmic A+/A- RNA extraction 
 Cytoplasmic RNA was diluted to <500 µg/ml in sterile buffer E (0.1 M Tris, 1 M 
EDTA and 0.1% SDS) and passed over oligo-dT columns.  The A- RNA fraction was 
recovered from the flow-through by ethanol precipitation.  The A+ RNA fraction was 
eluted with Buffer A (0.1 M Tris, 1 mM EDTA, 0.1% SDS and 0.2 M NaCl), ethanol 
precipitated and resuspended to 0.5 µg/µl.. 
 
RNA ANALYSIS 
S1 nuclease protection assay 
 Expression of the exogenous IgM gene was analyzed by the S1 nuclease 
protection assay utilizing a 3’ end-labeled probe that differentiates cleaved and 
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polyadenylated µs mRNA from spliced µm mRNA (Peterson et al., 2002; Peterson and 
Perry, 1989).  The probe corresponds to a 640 bp region containing the Cµ4 exon and 
part of the intron downstream of the µspA, as well about 30 bp of unrelated sequence 
(see Figure 3.2).  The 640 bp probe was PCR amplified from 100 ng of any Cµ plasmid 
DNA with primers “Pst-T” and “Hind” (Table 2.2) for 30 cycles of 1 minute at 94°C, 2 
minutes at 55°C and 2 minutes at 72°C.  The PCR product was purified using the QIAEX 
II desalting and concentrating DNA protocol following manufacturer instructions, and 200 
ng of PstI-digested fragment was 3’-end labeled using the Klenow fragment of DNA 
polymerase I and [α-32P]-dCTP.  The 3´end-label PCR product was purified through a 
Centri-Spin-20 column (Princeton Separation, N.J) and its specific activity (cpm) was 
determined in a scintillation counter. 
A total of 100 µg of RNA containing 10 µg of either M12 or S194 RNA and carrier 
RNA were precipitated along with 20,000 cpm of 3´-end-labeled probe.  The pellet was 
resuspended in 50 µl of hybridation solution (80% formamide, 0.6 M NaCl, 10 mM 
PIPES, 1mM EDTA) and incubated overnight at 50°C after denaturation for 15 minutes 
at 80°C.  The S1 nuclease digestion was carried out by adding 450 µl of S1 buffer (3 mM 
Zinc acetate, 30 mM sodium acetate and 250 mM NaCl) and 60 units of S1 nuclease 
(Invitrogen), incubating at 37°C for 30 minutes.  Protected fragments were extracted with 
chloropane, precipitated with ethanol and analyzed on a 6 % denaturing polyacrylamide 
gel (6 % acrylamide/bis-acrylamide, 7 M urea) at 350 V for 1 hour.  The dried gel was 
quantitated using Phosphorimage analysis and ImageQuant 5.0 (Molecular Dynamics). 
 
In Vitro transcription 
 To synthesize a control RNA for reverse transcriptase (RT) reactions, a 2976-bp 
EcoRV fragment of µ gene was subcloned into pGEM4.  This fragment contains about 
594-bp upstream of the M1 exon (including the KpnI site) and 1900-bp downstream of 
µm pA.  This fragment was in vitro transcribed from pGEM-RV using SP6 RNA 
polymerase (Promega) and the Ampliscribe transcription kit (Epicentre) following the 
manufacturer instructions.  Briefly, 10 µg of pGEM-RV was linearized with BamHI 
followed by chloropane extraction and ethanol precipitation.  The pellet was 
resuspended in water at 1 µg/µl and 2 µg of the BamHI-linearized pGEM-RV was in vitro 
transcribed by incubation at 37°C for 90 minutes in presence of 10 mM DTT, 80 U of 
RNaseout (Invitrogen), 0.5 mM of each rNTP and 17 U of SP6 (Promega).  The sample 
was treated with 2.5 U of RQ1 DNase I (Promega) for 15 minutes at 37°C follow 
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chloropane extraction and ethanol precipitation. The pellet was resuspended in 6 µl of 
water and 2 µl was electrophoresed on a 1 % agarose formaldehyde gel and visualized 
by ethidium bromide staining to ensure it was intact. One µl of a 1:1000 dilution of the in 
vitro transcribed RNA was used for the reverse transcription reactions with a µ sequence 
specific primer and 1 µl of the 1:10 diluted RT reaction was used for PCR reactions. 
 
Reverse Transcriptase-PCR (RT-PCR) 
 One to two µg of total RNA was reverse transcribed with hexamer random 
primers (Invitrogen) or a gene-specific primer using the Omniscript RT Kit (QIAGEN) 
following manufacturer instructions.  cDNA was PCR amplified using 1-5 µl of the 
(undiluted or 1:5 diluted) RT reaction.  To ensure the reactions were within the linear 
amplification range, PCR products were collected at different cycle numbers.  PCR 
products were analyzed on agarose gels containing ethidium bromide, photographed 
and when required, specific PCR product bands were quantified from the digital images 
using ImageQuant 5.0 (Molecular Dynamics).  All PCR reactions were performed with 
controls in which the reverse transcriptase was omitted from the reaction; all the RT(-) 
reactions were blank, indicating there was no DNA contamination in the RNA samples 
(data not shown). The images were often inverted for presentation in the figures. 
 For radioactive PCR, 40 ng of reverse primer was 5’-end labelled with γ-32P-ATP 
and polynucleotide kinase.  The 5´end-labeled primer was eluted through a Centri-Spin-
10 column (Princeton Separation, N.J) and its specific activity (cpm) was determined in a 
scintillation counter.  PCR reactions were performed as usual but in 25 µl final volume 
and containing 0.5 µl of 5’-end labelled primer and 5 µl of RT reaction.  PCR products 
were ethanol precipitated, resuspended in 5 µl of S1 loading buffer (80% formamide, 1 
mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol) and analyzed on a 6% or 8% 
denaturing polyacrylamide gel (6-8% acrylamide/bis-acrylamide, 7 M urea).  The PCR 
product bands were visualized from the dried gels using phosphorimage analysis. 
 
3´-Rapid amplification of cDNA-end by PCR (3’-RACE) 
 One µg of total RNA was reverse transcribed with a tagged-poly-dT primer (RT-
RACE primer) using the Omniscript RT Kit (QIAGEN) following manufacturer 
instructions. Five µl of synthesized cDNA was PCR amplified using a reverse primer 
targeting the 3´-end tag (3´RACE-1 primer) and a forward primer complementary to the 
Cµ3 exon (Cµ3T primer) for 35 cycles of 94°C for 1 minute, 56°C for 1 minute and 72°C 
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for 2 minutes. 5 µl of the PCR product was submitted to a nested PCR with the 
“3´RACE-1” primer and a forward primer complementary to the Cµ4 exon (Apa primer) 
for 35 cycles of 94°C for 1 minute, 52°C for 1 minute and 72°C for 2 minutes. Ten to 
twelve µl of PCR product were digested with 5 units of either NheI (Invitrogen) or SpeI 
(NEB) overnight at 37°C and digested and undigested samples were visualized by 
ethidium bromide staining in either 1.8% agarose gels or 8% non-denaturing 
polyacrylamide gels. 
 
TRANSGENIC MICE 
 Transgenic mice expressing the TTR-Flag-Zhx2 were generated in a (C57BL/6 × 
C3H) background by the University of Kentucky Transgenic Mouse Facility. Transgenic 
founders were bred to BALB/cJ mice and offspring were screened by PCR using DNA 
extracted from tail biopsies for the presence of the TTR-Flag-Zhx2 transgene and 
primers TTR and H1R.  The endogenous Zhx2 allele was assessed with primers Afr1, 
Afr2 and ETn3Flank.  Nuclear extracts or RNA were prepared from liver of 3 week old or 
older littermate with or without the Flag-Zhx2 transgene.   
 Transgenic mice expressing the AFP minigenes were generated in a (C57BL/6 × 
C3H) background by the University of Kentucky Transgenic Mouse Facility.  AFP cDNA 
and genomic minigenes were jointly constructed in the Peterson and Spear labs.  The 
AFP minigenes consist of the AFP exon 1 to exon 3 fused to the last two exons, exon 14 
and exon 15, in its genomic (intron containing) or cDNA (no introns) forms.  An 18 bp 
oligonucleotide was inserted into the Bsu36I site in exon 15 to distinguish the transgene 
form the endogenous gene.  The minigenes were linked to the AFP enhancer II and 
either the AFP 250 bp promoter or 1 kb AFP promoter/repressor regions.  Independent 
founders were crossed to BALB/cJ and two F1 from each founder were backcrossed to 
BALB/cJ.  F2 offspring were screened by PCR using DNA extracted from tail biopsies.  
Presence of 250-AFP minigenes were analyzed with primers AFP120+165R and 
AFPE2, the 1kb-AFP minigenes with primers E3F and E15R and presence of the mutant 
or wild-type Zhx2 allele with primers Afr1, Afr2 and ETn3Flank.  To determine Zhx2 
regulation of AFP minigenes, liver RNA was prepared from F2 transgenic mice and 
analyzed by RT-PCR with primers E3F or E14E15-F and E15R.  
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PROTEIN PREPARATION AND ANALYSIS 
Nuclear extract preparation from mouse liver 
 Nuclei from mouse liver were purified following the two sequential sucrose 
cushion procedure as described in the cellular RNA extraction section.  Purified nuclei 
obtained from two mouse livers were resuspended in 900 µl of low-salt buffer (20 mM 
HEPES pH 7.9, 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and 
proteinase inhibitors) using a 7 ml Dounce homogenizer and pestle B.  Equal volume of 
high-salt buffer (20 mM HEPES pH 7.9, 800 mM KCl, 25% glycerol, 1.5 mM MgCl2, 0.2 
mM EDTA, 0.5 mM DTT and proteinase inhibitors) was added in a dropwise fashion to 
the nuclei suspension while mixing with the pestle B.  The extract was incubated for 30 
minutes at 4ºC with gentle mixing and transferred to a 2 ml microcentrifuge tube.  
Nuclear extract was obtained by centrifugation at 21,000×g for 30 minutes at 4ºC.  
Aliquot of supernatants (NE) were quickly frozen in liquid nitrogen and storage at -80ºC.  
Pellets were resuspended in 900 µl of 8M urea and 900 µl of 2X loading buffer (125 mM 
Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.02% bromophenol blue, 0.2 M DTT) and 
incubated for 4-5 minutes in a boiling water bath.  Total nuclei suspension in low-salt 
buffer, nuclear extract and suspended pellet were analyzed by 8% SDS-PAGE, 
transferred to PVDF membrane and blotted with anti-Zhx2 and/or anti-Flag antibodies.   
 
Nuclear extract preparation from HEK293 cells 
 HEK293 cells transiently transfected with a Flag-Zhx2-expressing plasmid were 
harvested, washed with PBS (4.3 mM Na2HPO4, 1.4 mM KH2PO4, 137 mM NaCl, 2.7 
mM KCl, pH 7.4) and prepared nuclear extract using the NE-PER nuclear and 
cytoplasmic extraction reagent (Thermo Scientific) following the instruction manual.  
Total protein was determined by BCA protein assay and 2.5 to 5 µg of total protein was 
used as positive control in Western blot analysis with anti-Flag or anti-Zhx2 antibodies. 
 
Flag-tagged Zhx2 immunoprecipitation 
 Immunoprecipitation was performed by batch absorption following the instruction 
manual of the anti-Flag M2 affinity gel (Sigma).  Nuclear extracts (100 µg) were 
resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X-100) up to a final volume of 500 µl and incubated overnight with 10 µl of packed 
volume of beads previously equilibrated with TBS.  The beads were washed three to four 
times with 500 µl of TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl) and elute with 20 µl of 
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2X loading buffer incubated 4 minutes in boiling water bath.  Beads were collected by 
centrifugation at 7000×g for 1 minute and the eluate was analyzed by Western blot. 
 
Western blotting 
 Protein samples from total nuclei suspension, nuclear extracts or insoluble 
pellets were fractionated on 8% SDS-PAGE and electro-blotted to PVDF (Polyvinylidene 
fluoride) membrane (Immobilon-P, Milipore) as described by Ausbel et al. (Ausubel et 
al., 1987).  Filters were blocked 2 hours or overnight with blocking buffer (20 mM Tris-
HCl pH 7.6, 140 mM NaCl, 0.1 % Tween-20 and 5% non-fat dry milk).  Membranes were 
was incubated 2 hours at room temperature or overnight at 4ºC with primary antibody 
diluted in blocking buffer and then washed 4 times with TBST (20 mM Tris-HCl pH 7.6, 
140 mM NaCl, 0.1 % Tween-20).  Membranes were incubated with secondary antibody 
2 hours at room temperature, washed 4 times with TBST and bands were visualized by 
enhanced chemiluminescence (Pierce).  Primary antibodies used: monoclonal mouse 
anti-Flag M2 (Sigma) 1:500 dilution; polyclonal rabbit Anti-Zhx2 (Bethyl laboratories) 
1:2000 dilution. Secondary antibodies used: goat anti-mouse IgG-HRP (sc-2031) 1:4000 
dilution and goat anti-rabbit IgG-HRP (sc-2004) 1:8000 dilution. 
 
BCA protein assay 
Total protein concentration from nuclear extracts was determined by BCA (PIERCE), 
following the instruction manual. 
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Table 2-1: Plasmid constructs used in Cµ study. 
Plasmid Construct 
pGEM-T-CoTCa β-globin CoTC (800 bp) PCR product cloned into pGEM-T 
Cµ c Intact Ig µ gene in the pR-SP6 plasmid backbone 
∆NH d Intact Ig µ gene containing a 158 bp deletion of the pause element between NotI and HindIII sites 
∆AR b Intact Ig µ gene containing a 797 bp deletion between AccI and EcoRV sites 
∆NR b Intact Ig µ gene containing a 351 bp deletion between NcoI and EcoRV sites 
∆AN b Intact Ig µ gene containing a 446 bp deletion between AccI and NcoI sites 
∆AR/pBR403 b 403 bp fragment from pBR322 inserted in the KpnI site of ∆AR 
∆AR/rpI900 b 900 bp fragment from the intron of the S16 ribosomal protein gene (rpI900) inserted at the KpnI site of ∆AR 
Cµ/rpI900 b rpI900 fragment inserted at the KpnI site of Cµ 
Cµ/CoTC(+)a β-globin CoTC inserted in 5’-3’ orientation 1200 bp downstream of µspA (KpnI site) of Cµ 
Cµ/CoTC(-)a β-globin CoTC inserted in 3’-5’ orientation 1200 bp downstream of µspA (KpnI site) of Cµ 
∆NH/CoTC(+)a β-globin CoTC inserted in 5’-3’ orientation 1042 bp downstream of µspA (KpnI site) of ∆NH 
∆NH/CoTC(-)a β-globin CoTC inserted in 3’-5’ orientation 1042 bp downstream of µspA (KpnI site) of ∆NH 
∆AR/CoTC(+)a β-globin CoTC inserted in 5’-3’ orientation 403 bp downstream of µspA (KpnI site) of ∆AR 
∆AR/CoTC(-)a β-globin CoTC inserted in 3’-5’ orientation 403 bp downstream of µspA (KpnI site) of ∆AR 
Cµ/CoTC-Ha β-globin CoTC inserted in 5’-3’ orientation 200 bp downstream of µspA (HindIII site) of Cµ 
∆NH/CoTC-H a β-globin CoTC inserted in 3’-5’ orientation 50 bp downstream of µspA (HindIII site) of ∆NH 
Cµ/rpI900-H a rpI900 fragment inserted 200 bp downstream of µspA (HindIII site) of Cµ 
∆NH/rpI900-H a rpI900 fragment inserted 50 bp downstream of µspA (HindIII site) ∆NH 
a This work 
b Peterson and Perry (1986) 
c Peterson and Perry (1989) 
d Peterson et al (2002) 
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Table 2-2: Oligos used for reverse transcriptase and PCR reactions in Cµ study. 
  
CoTC-Fc (#342): 5’ ACTTAGGTACCATAGTGTTACCATCAACCACC 3’ 
CoTC-R800 (#344): 5’ ACAATGGTACCTCCCACCCCCAACCCCT 3’ 
Hind (#4): 5’ ATATGTGCCTGAATGCTGCC 3’ 
Pst-T (#264): 5’ TGGTGAAGGGCTTCTCTCCTG 3’ 
RT-RACE (#48): 5’ AGAGAATTCACCGGATCCTACCCGGGTTTTTTT 3’ 
3´RACE-1(#51): 5’ GAGAATTCACCGGATCCTAC 3’ 
Apa (# 7): 5’ TATGTGACCAGTGCCCCGAT 3’ 
Cµ3T (#86): 5’ TGACTCACAGGGATCTGCCT 3’ 
C4B (#274): 5’ CATTCCTCCTCTGTCACAGTCAGG 3’ 
CµpA-T (#242): 5’ CCTGGGTGTCCAGTTGCTCTGT 3’ 
432AS (#246): 5’ TGTACCTTTGTCTGTGTGTCCATGA 3’ 
1528AS (#248): 5’ GGCAGACTCAGGAACTGTGGCA 3’ 
Kpn-T (#265): 5’ GATCAGAGATCCCAATAAATGCCC 3’ 
Kpn-B (#278): 5’ AAGGACTCGGACATCTCATGACTTT 3’ 
M1-B (#277): 5’ CAAAGCCTTCCTCCTCAGCATT 3’ 
M2-T(#279): 5’ TGTACAATCTGAAGCAATGTCTGGC 3’ 
M2-B (#280): 5’ CAGATAATCCTTGGGCTGTCAACA 3’ 
469-T (#281): 5’ TGGGTGTGCCTTTGGGGAGT 3’ 
469-B (#282): 5’ GCCTTTATCTGTCCTCGAGTGACT3’ 
473AS (#546): 5’ AGGGACCATCACCAAGGTGC 3’ 
982AS (#548): 5’ TAGCTCTGAGGTCATGGCGGGT 3’ 
 
 
Table 2-3: Oligos used for PCR reactions in Zhx2 study. 
 
TTR (#110S): 5’ TGTTCCAGAGTCTATCACCG 3’ 
B-ActF (#131): 5’ GTGGGCCGCTCTAGGCACCA 3’ 
B-ActR (#132): 5’ CGGTTGGCCTTAGGGTTCAGGGGGG 3’ 
L30R (#138): 5’ CCTCAAAGCTGGACAGTTGTTGGCA 3’ 
AFPE12A (#267): 5’ TGAGCTTGGCACAGATCCTTGTGGA 3’ 
E1E5H19-F (#322): 5’ TCCAGAGTCCGTGGCCAAGGAGG 3’ 
E1E5H19-R (#323): 5’ TGGATTCTCAGGGGTGGGTGGGT 3’ 
E2E3-F (#324): 5’ TCCACGTTAGATTCCTCCCAGTGCG 3’ 
E2E3-R (#325): 5’ TGTTCACTTCCTCCTCGGTGGCTTC 3’ 
E5E6-R (#327): 5’ TTGCCTGGAGGTTTCGGGATCC 3’ 
E10E11-F (#330): 5’ TGCAGAAACACATCGAGGAGAGCCA 3’ 
E10E11-R (#331): 5’ CGTGGAGGCAATGCTCACCATCTTC 3’ 
E14E15-F (#334): 5’ GGTCCAAAGTTGATTTCCAAAACTC 3’ 
E13E15-F (#337): 5’ GCCAAAAGGCTCACACCAAAGAGTC 3’ 
E11E12F (#373): 5’ TTATTGGTTACACGAGGAAAGCCC 3’ 
E12E13-FB (#377): 5’ GCCGACATTTTCATTGGACATTTGT 3’ 
E12E13-RB (#378): 5’ CAGACTTCCTGGTCCTGGGCTTT 3’ 
Afp3’-F (#396): 5’ TTGATTTCCAAAACTCGTGATGC 3’ 
Afp3’-R1 (#397): 5’ GAAATCTCACATGGACATCTTCACC 3’ 
Afp3’-R2 (#398): 5’ TCAGAGGAGAAGTGGAATGGTGA 3’ 
H1R (#405S): 5’ CCCATAGATTTCACCTCAACC 3’ 
Gpc3 U-2 (#423): 5’ TGACCGTGACCTTGAGCGTC 3’ 
nest12-13BF (#432): 5’ TTCTCCCAGTTTTCTTCACCCCAG 3’ 
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nest12-13BR (#433): 5’ AACCCTAGCAGCCATCCTCAG 3’ 
Gpc3E7-U (#438): 5’ ACGGGATGGTGAAAGTGAAGAAT 3’ 
Gpc3E8-L (#440): 5’ CGCTGTGAGAGGTGGTGA 3’ 
H19Ex2-L (#443): 5’ AAGAAGGCTGGATGACTG 3’ 
S-H19 (#463S): 5’ CGTTCTGAATCAAGAAGATGCTGC 3’ 
AS-H19 (#464S): 5’ TTTGAGTCTCTCAAGCAAGGAAGG 3’ 
E1F (#499): 5’ GTGAAGGAACCAGCAGCCATGA 3’ 
E3F (#500) 5’ AATGACTAGCGATGTGTTGGCTGC 3’ 
E14R (#501): CGCCCAAAGCATCACGAGTTT 3’ 
E15R (#502) 5’ TTCCTAAGGCAAGCTTCGAGGCT 3’ 
U6F (#579): 5’ GTGCTCGCTTCGGCAGCACATATA 3’ 
U6R (#580): CGAATTTGCGTGTCATCCTTGCG 3’ 
L30F2 (#581): 5’ TGTCCCGCACCTAAGGCAGGAAGAT 3’ 
i9-F (#596): 5’ AAGGCAAAATCTCCTGTCCAGTGG 3’ 
i10-R (#597) 5’ GGTTTGGGGAACCCGAAGTCAAT 3’ 
i10-F (#598) 5’ TCAAGGAAGAGCTAAGGTTGGGAGG 3’ 
i11-R (#599) 5’ TTTGAGAAGGACAGAACGCCTGGC 3’ 
i2-F (#600) 5’ CTGAGTGACTCGAACCCAGTTTCCC 3’ 
i2-R (#601) 5’ CTGGAACTCCAGTCAATGTCAAGGC 3’ 
i3-R (#602) 5’ GGCGGGATTCCAGAACTAATCG 3’ 
i5-R (#605) 5’ CCCACAGGAGGCACATTTCTGC 3’ 
i1-F (#607) 5’ TGTGAGGGAGCCAAGTAGTAAGGG 3’ 
E5-F (#608) 5’ TGCCCCAGCCATTCTGTCCT 3’ 
Z2HD1-F (#1017S): 5’ TCCCCGTCCCGCTGAATACT 3’ 
Z2HD1-R (#1018S): 5’ TGTGCTCCTCTGGGTGTTTG 3’ 
Gpc3URT (1031S) 5’ CTCCCAGCAACGCCAATATAGATC 3’ 
Gpc3LRT (1032S) 5’ CTGATTCTTCATCCCGTTCCTTGC 3’ 
H19Ex2-U (#1128S) 5’ ACAGAAGGGCAGTCATCCAG 3’ 
H19Ex3-L2 (#1129S) 5’ CCAGAGAGCAGCAGAGAAGT 3’ 
H19Ex3-L3 (#1131S) 5’ GTTCAAGGTAGGGGGAGGAG 3’ 
Afr1 (#1143S) 5’ AACCCAAGTAGCAAGTGAGTGGTG 3’ 
Afr2 (#1144S) 5’ ATCTCTGGTCCAGTAGAAAGGTGC 3’ 
ETn3Flank (#1259S) 5’ CCTATCTTGGTACCCTGATCAAGC 3’ 
AFP120+165R (#1276S) 5’ CCTTACGTTGAAGTTAGGCAA 3’ 
AFPE2 (#1280S) 5’ GATCTGGATCCGGGGAAATAATCT 3’ 
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CHAPTER III 
AFP SPLICING REPRESSION BY ZHX2 
 
INTRODUCTION 
 That transcription and post-transcriptional events are closely associated is 
suggested by interactions between components involved in transcription initiation, 
elongation and termination with those involved in RNA processing (capping, splicing and 
cleavage and polyadenylation).  Coupling transcription with RNA processing is mediated, 
at least in part, by the C-terminal domain (CTD) of the RNAPII largest subunit, which 
contains multiple heptapeptide repeats that are targets of regulated phosphorylation.  
Dynamic changes in CTD phosphorylation are involved in modulating recruitment of 
factors required for elongation and RNA processing in a temporal-spatial manner.  
During transcription initiation, the RNAPII CTD is phosphorylated at serine 5 of the 
heptapeptide (S5), resulting in recruitment of DSIF and NELF to the transcription 
complex (Figure 1-1).  This induces a promoter proximal pausing that allows binding of 
capping enzymes.  Pausing is relieved by phosphorylation of the RNAPII CTD at serine 
2 (S2), mediated by recruitment of pTEFb to the elongation complex.  This causes 
dissociation of NELF and transcription elongation proceeds (Bentley, 2002; Bres et al., 
2008; Mandal et al., 2004; Sims et al., 2004b).  Although under certain conditions, it has 
been reported that RNAPII elongation could proceed in the absence of pTEFb, the 
coupling of transcription with RNA processing is disrupted, giving rise to full-length RNA 
transcripts that are quickly degraded (Hargreaves et al., 2009).  Such is the case of 
primary response genes in unstimulated macrophages.  Soon after activation, pTEFb is 
recruited to the elongation complex and RNA processing is reestablished to allow rapid 
production of mature mRNA (Hargreaves et al., 2009).  Additionally, promoter structure 
has also been implicated in coupling transcriptional and post-transcriptional events to 
control gene expression.  Studies with reporter minigenes containing the alternative 
exon (E33 or EDI) of the fibronectin (FN) gene showed that FN and CMV promoters 
induced 10 times higher inclusion of the exon E33 compared to the α-globin promoter 
(Cramer et al., 1999; Cramer et al., 1997; Kornblihtt, 2005, 2006).  Therefore, post-
transcriptional events can be modulated by altering the elongation properties of the 
RNAPII in the pre-initiation complex.  This may result in changes in elongation rates or 
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recruitment of RNA processing factors and ultimately may have effect on the fate of the 
nascent transcript and regulate gene expression (Kornblihtt, 2005).   
 Expression of the AFP gene is developmentally regulated.  It is expressed at high 
levels in fetal liver and dramatically repressed after birth.  Interestingly, AFP expression 
is reactivated in hepatocellular carcinomas and during liver regeneration.  Because of 
this characteristic pattern of AFP gene expression, it has become an important model for 
liver-specific gene expression during liver development, liver regeneration and disease 
(Spear et al., 2006).  The first information about the mechanism of AFP repression was 
obtained by screening adult serum AFP levels of different inbred mouse strains (Olsson 
et al., 1977).  All the strains expressed low serum levels of AFP with the exception of 
BALB/cJ mice that expressed about 10 to 20-fold higher levels than the other mouse 
strains analyzed.  Post-natal persistence of AFP expression in BALB/cJ mice is due to a 
mutation in the Zinc-fingers and homeoboxes 2 (Zhx2) gene (Blankenhorn et al., 1988; 
Olsson et al., 1977; Perincheri et al., 2005), a member of a small family of proteins that 
contains two zinc fingers and four or five homeodomains (Spear et al., 2006).  Analysis 
of the BALB/cJ Zhx2 allele revealed the presence of a mouse endogenous retrovirus 
(MERV) element that interferes with proper splicing of the Zhx2 transcript, 
downregulating its expression in this mouse strain (Perincheri et al., 2008).  Lower Zhx2 
levels in adult BALB/cJ liver correlate with increased accumulation of AFP and H19 
mRNA levels, indicating the role of Zhx2 in repressing expression of these genes after 
birth.  Other Zhx2 target genes identified are Gpc3 (Morford et al., 2007) and Lpl 
(Gargalovic et al., 2010)  Both showed developmental expression patterns similar to the 
AFP and H19 genes, high in fetal liver, repressed after birth and reactivated in liver 
cancer and during regeneration (Gargalovic et al., 2010; Morford et al., 2007; Spear et 
al., 2006). 
 Transgenic mouse studies using minigenes or other reporter genes linked to 
different portions of the AFP 5’ flanking sequences have been used as a strategy to 
better understand the mechanism of AFP repression mediated by Zhx2.  The 250 bp 
AFP promoter was sufficient to confer Zhx2 regulation to a linked reporter gene (H-2Dd) 
suggesting that Zhx2 acts at transcriptional level (Peyton et al., 2000a).  However, 
transcriptional rates on the AFP and H19 genes, measured by nuclear run-on assays, 
were the same in the presence or absence of Zhx2 expression, indicating that Zhx2 may 
act at post-transcriptional level (Morford; Vacher et al., 1992).  Based on these results, it 
was proposed that Zhx2 controls accumulation of mRNA levels of targets genes by a 
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mechanism that couples transcription and post-transcriptional events (Peyton et al., 
2000a).  Therefore, we explored splicing as possible post-transcriptional step involved in 
Zhx2 regulation and indeed, we found that splicing of AFP was repressed in the 
presence of Zhx2.  We further investigated whether introns are required for splicing 
regulation and whether alternative splicing plays a role in AFP post-natal repression 
mediated by Zhx2.  We also analyzed the splicing efficiency of the H19 and Gpc3 genes, 
two other Zhx2 target genes.  Preliminary results found no evidence of splicing inhibition 
in these genes in response to Zhx2.  To investigate possible factors controlled by Zhx2 
that are involved in coupling transcription and RNA processing, we intend to purify and 
identify proteins that interact with Zhx2.  Toward this end, we initiated optimization of 
nuclear extracts preparation and immunoprecipitation assays that eventually will lead to 
purification of the Flag-tagged Zhx2 and its interacting proteins.   
 
RESULTS 
AFP splicing repression mediated by Zhx2 
 Based on the preliminary data described above, it was proposed that Zhx2 
regulates AFP expression through a post-transcriptional mechanism controlled by the 
AFP promoter.  To determine what post-transcriptional step is involved in that regulation, 
splicing efficiency across the AFP gene was analyzed first.  Total liver RNA from adult 
littermate mice with or without the Flag-tagged Zhx2 transgene was utilized for cDNA 
preparation using random hexamers.  PCR amplification was performed with sets of 
primers spanning several exon-exon boundaries throughout the AFP gene (Figure 3-1).  
Data from the PCR reactions diagrammed in Figure 3-1, along with the expected sizes 
for the unspliced and/or spliced AFP transcripts are shown in Figure 3-2.  Ribosomal 
protein L30 (rpL30) was used as an expression control.  Negative controls without RT 
enzyme were performed and no signal corresponding to PCR products for L30, H19 or 
AFP E10-E11 were observed, indicating there was no DNA contamination (Figure 3-2).  
When primers targeting several exon-exon regions was performed (Figure 3-2, top 
panels: AFP E2-E3, AFP E5-E6, AFP E10-E11, AFP E12-E13, AFP E14-E15), samples 
from animals expressing Flag-Zhx2 showed lower accumulation of spliced mRNA than 
that observed from samples of animals not expressing Flag-Zhx2.  This result is 
consistent with previous data that showed AFP and H19 mRNA accumulated to higher 
levels in BALB/cJ mice (no Zhx2 expression).  Interestingly, PCR analysis of AFP E10-
E11, AFP E12-E13 and E14-E15 (Figure 3-2, top panels of AFP E10-E11, AFP E12-E13 
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and AFP E14-E15) showed that in the presence of Zhx2, bands corresponding to 
unspliced RNA were detected with higher intensity than those observed in the absence 
of Zhx2.  This suggested that AFP splicing efficiency across multiple exons within the 3’-
end of the AFP gene was substantially reduced in Zhx2-expressing animals.  To verify 
differences in unspliced RNA levels between mice with or without Zhx2, PCR reactions 
with primers targeting exon-intron or intron-intron boundaries were performed.  This 
strategy will only detect unprocessed RNA.  In all the cases assessed (Figure 3-2, 
middle and bottom panels of AFP E2-E3, AFP E5-E6, AFP E10-E11, AFP E12-E13, AFP 
E14-E15), bands corresponding to the unspliced RNA showed higher intensity in the 
presence of Zhx2 than in the absence of Zhx2.  This strategy allowed detection of PCR 
product due to unprocessed RNA in E2-E3 and E5-E6 and indicated that AFP splicing 
repression mediated by Zhx2 is extended towards the 5’-end.  Therefore, we conclude 
that Zhx2 has a general effect on the splicing efficiency throughout the AFP gene which 
would explain the reduced accumulation of AFP mRNA in adult BALB/cJ mice. 
 
Analysis of cellular RNA fractions 
 Preliminary data demonstrated that Zhx2 was enriched in the chromatin-
associated (insoluble) fraction, which is consistent with the idea that Zhx2 may be 
involved in a co-transcriptional regulation step.  Therefore, the unprocessed RNA 
observed in the presence of Zhx2 may be more abundant in the nuclear fraction.  To 
explore the cellular localization of the unspliced RNA, liver tissue from littermate mice 
with or without the Flag-tagged Zhx2 transgene was fractionated into cytoplasmic, 
chromatin soluble (NSol) and chromatin-associated (insoluble, NIns) fractions (Pandya-
Jones and Black, 2009).  RNA was extracted from each fraction, cDNA was made with 
random hexamers and AFP expression was analyzed by PCR using primers spanning 
AFP E10-E11 (Figure 3-3).  β-actin and rpL30 were utilized as loading controls.  U6 
RNA, which is found exclusively in the nucleus, was used as a fractionation control.  A 
U6 RNA PCR product was observed only in the nuclear soluble and nuclear insoluble 
fractions as expected, indicating that cytoplasmic fraction was clean.  A PCR signal was 
not detected in the nuclear insoluble fraction using primers targeting the AFP E10-E11 or 
L30, suggesting that the spliced RNAs must be rapidly released from the chromatin and 
unspliced AFP RNA is not retained in this fraction.  However, PCR products from the β-
actin and U6 reactions were visible, indicating that the RNA in this fraction was not 
degraded and thus, the absence of AFP E10-E11 PCR product was due to low 
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abundance of the AFP transcript in this fraction.  In the nuclear soluble fraction, both 
spliced and unspliced AFP E10-E11 was detected and relatively more of the PCR band 
corresponding to the spliced RNA was seen in absence of Zhx2.  Thus, the Zhx2 
regulation of mature mRNA abundance is seen in the nucleus, consistent with this being 
due to a nuclear regulatory event.  However, there wasn’t an obvious difference in the 
unspliced PCR product in the presence or absence of Zhx2.  Surprisingly, a dramatic 
difference was observed in the cytoplasmic fraction in which high accumulation of the 
unspliced RNA was observed in presence of Zhx2 with concomitant lower levels of 
spliced RNA, compared to that observed in absence of Zhx2.  Negative controls without 
RT enzyme were performed and no signal corresponding to PCR products for L30, β-
actin or AFP E10-E11 were observed, indicating there was no DNA contamination (data 
not shown).  This experiment was repeated with the cytoplasmic RNA fraction from other 
independent sets of littermate mice and the same result was observed.  Additional RT-
PCR reactions were performed with primer pairs spanning different exon-exon and exon-
intron boundaries (as shown in Figure 3-1) using the cytoplasmic RNA fractions (results 
not shown).  In all cases, higher levels of unspliced product was observed in presence of 
Zhx2, indicating that unprocessed AFP transcripts are present in the cytoplasm and thus 
have escaped from nuclear surveillance processes. 
 The cytoplasmic fraction was further characterized by analyzing poly-A+ and poly-
A- RNA fractions by RT-PCR.  A+ and A- RNA fractions were obtained from liver 
cytoplasmic RNAs by separation through oligo-dT columns.  cDNA was made from each 
fraction utilizing random hexamers and PCR reactions were performed with primers 
targeting AFP E10-E11, E14-E15 and L30 as an internal control (Figure 3-4).  In the A+ 
fraction, the AFP E10-E11 spliced PCR product was mainly detected in absence of 
Zhx2, consistent with the known mRNA expression differences seen in the presence or 
absence of Zhx2.  The unspliced product was not detected in either of the A+ RNA 
fractions, indicating that the unspliced RNA is not polyadenylated.  Indeed, the main 
PCR product observed in the A- fraction corresponded to the unspliced RNA, which was 
more abundant in presence of Zhx2.  Similar results in both the A+ and A- fractions were 
seen with the AFP E14-E15 primers.  Although it was unexpected to find unspliced RNA 
in the cytoplasmic fraction, there are some reports in the literature that unspliced RNAs 
are found in the cytoplasm when splicing is inhibited with small molecules or mutations 
in the core splicing machinery (Kaida et al., 2007; Legrain and Rosbash, 1989; O'Brien 
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et al., 2008).  Therefore, the data discussed here is consistent with global repression of 
AFP splicing mediated by Zhx2. 
 
Splicing analysis of other known targets of Zhx2 
 Other known targets of Zhx2 are the H19 and Gpc3 genes.  We proceeded to 
investigate whether Zhx2 may regulate expression of these genes by repressing pre-
mRNA splicing as was observed with AFP.   Conventional RT-PCR was used to analyze 
Gpc3 splicing in the presence and absence of Zhx2.  Both cytoplasmic and nuclear 
soluble fractions were used for cDNA preparation.  PCR reactions were performed with 
pairs of primers targeting exon and intron boundaries across the Gpc3 gene (Figure 3-
5).  Higher accumulation of spliced Gpc3 mRNA (PCR E4-E6 and PCR E7-E8) was 
observed in absence of Zhx2 in both cytoplasmic and nuclear soluble fractions, though 
the difference in abundance was not as obvious as that observed in the AFP gene as 
seen previously (Morford et al., 2007).  Unspliced product (Gpc3 I5-E6) was not detected 
in the cytoplasmic fraction and little difference in accumulation was seen in the nuclear 
soluble fraction.  PCR product signals for the unprocessed RNA were significantly 
weaker than those observed for the spliced RNA, indicating that unprocessed transcripts 
are present in lower abundance.  To examine H19 splicing, primers in Exons 4 and 5 
were used (Figure 3-5).  No unspliced RNA was detected, but again, the repression due 
to Zhx2 was seen in both the cytoplasmic and nuclear fractions.  The fact that the Zhx2 
regulation was seen in the nuclear RNA fraction is consistent with this being due to a 
nuclear regulatory event, but it is not clear whether splicing is the regulated event for the 
Gpc3 and H19 genes. 
 Preliminary data had indicated that unspliced H19 RNA could not be detected by 
conventional RT-PCR.  Therefore, PCR amplification was performed using a 5’-end 
radiolabeled primer to increase sensitivity.  Splicing analysis across the H19 gene was 
performed by using pairs of primers that target different exons of the H19 gene, 
diagrammed in Figure 3-6A.  The cytoplasmic RNA fraction was used for cDNA 
preparation because this fraction showed the higher difference in unprocessed AFP 
RNA.  In all the cases, higher accumulation of mRNA was observed in the absence of 
Zhx2, which is consistent with previous Northern blot data (Figure 3-6B).  However, 
unspliced H19 RNA could not be detected by this procedure; genomic DNA was used as 
a control to identify the correct size of unspliced RNA.  There are several possible 
explanations for this outcome.  One possibility is that splicing of H19 transcripts may be 
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repressed but the unprocessed RNAs are rapidly turned over before they can reach the 
cytoplasm.  In fact, unspliced RNAs are usually rapidly degraded in the nucleus, so this 
result with the H19 RNA may be expected.  To detect splicing repression, it may be 
better to examine nuclear RNA fractions.  On the other hand, the H19 gene is small, 
about 3.6 kb, compared to the AFP gene that is 20 kb, and consists of five exons 
separated by unusually short introns (~79-87 bp) which may favor efficient splicing.  
Thus, it is also possible that H19 is post-transcriptionally regulated at a step later than 
splicing repression   
 
Are introns required for Zhx2 regulation of target genes? 
 As discussed previously, the transcriptional rate across the AFP and H19 genes 
are similar in spite of Zhx2 expression.  However, in the presence of Zhx2 there is a 
decrease of mRNA levels compared to that observed in absence of Zhx2.  This 
difference in accumulated mRNA can be explained by general splicing inhibition of AFP 
pre-mRNA mediated by Zhx2.  Early transgenic mouse studies utilized the AFP promoter 
to drive expression of AFP minigenes or the MHC class I H-2Dd (250AFP-Dd) gene, both 
containing introns.  These transgenes were developmentally repressed and regulated by 
Zhx2 in a pattern similar to the endogenous AFP gene (Peyton et al., 2000a).  However, 
when Zhx2 was transiently co-transfected into liver cell lines with intron-less luciferase 
reporter genes driven by the AFP promoter, only about a 2-fold repression was observed 
(Shen et al., 2008).  It is possible that the lower fold repression observed with the 
luciferase reporter gene is because introns may be required for or contribute to Zhx2 
regulation.  This hypothesis was tested using AFP minigenes that differ only by the 
presence or absence of introns in littermate mice that either express the endogenous 
Zhx2 gene or have the mutant BALB/cJ allele.  If introns are required for Zhx2 
regulation, Zhx2 should regulate expression of the genomic AFP minigene whereas the 
cDNA AFP minigene expression should not be regulated. 
 To test the prediction that introns are required for Zhx2 regulation, the AFP 
minigenes diagrammed in Figure 3-7 were made, based on those used in previous 
studies that are known to be repressed at birth and responsive to Zhx2 expression 
(Peyton et al., 2000a; Vacher et al., 1992).  These AFP mini-genes consist of the AFP 
enhancer 2 and the 250 bp AFP promoter linked to AFP exon 1 through 3 fused to the 
last two AFP exons (250AFP-MG), exon 14 and 15, either containing (genomic) or 
lacking introns (cDNA).  Additionally, an insertion of 18 bp was included within exon 15 
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to allow exclusive detection of the AFP transgene.  The AFP minigenes were sequenced 
and their expression was tested in HepG2 cells before being introduced into mice.  Both 
genomic and cDNA AFP minigenes, were expressed at similar levels in HepG2 cells (A. 
Ribble, data not shown).  The AFP transgenes were introduced into mice expressing the 
wild-type Zhx2 allele.  Only one founder from each line was obtained and each 
backcrossed twice with BALB/cJ mice to determine whether these transgenes were 
responsive to Zhx2 regulation.  Total RNA from adult liver of littermate mice from each 
line was analyzed by RT-PCR using primers targeting exon 3 and the 18-bp sequence 
inserted within exon 15 (Figure 3-7).  Endogenous AFP and H19 RNA levels were 
analyzed by RT-PCR as controls for Zhx2 responsiveness and L30 was used as an 
expression control.  In both the cDNA and genomic AFP minigene transgenic lines, 
lower levels of endogenous AFP and H19 mRNA were observed in transgenic mice 
expressing Zhx2 wild-type allele (Zhx2+), as was unspliced AFP RNA.  In contrast, 
higher levels of endogenous AFP and H19 mRNA were observed in absence of Zhx2 
expression, indicating that the endogenous Zhx2 targets genes were regulated in both 
mouse lines, as expected.   
 Analysis of RNA from five transgenic littermate mice expressing the AFP cDNA 
minigene showed that this transgene was responsive to Zhx2 regulation; lower minigene 
mRNA levels were detected in mice that expressed the Zhx2 wild-type allele (Figure 3-7, 
left panel; Zhx2+) compared to mice with the BALB/cJ allele (Figure 3-7, left panel; 
Zhx2-).  The estimated fold-repression of the AFP cDNA transgene was about 3 to 4-fold 
while the endogenous H19 and AFP genes were repressed about 15-23-fold and 10-30-
fold, respectively.  This indicated that the cDNA AFP transgene was not repressed to the 
same extent as the endogenous AFP and H19 genes.  In contrast, analysis of the AFP 
genomic transgene, showed that it was not well expressed among the littermate mice 
tested (Figure 3-7, right panel) and therefore, it was difficult to assess whether this 
transgene was regulated.  There was high expression variability among littermates that 
did not correlate with the presence or absence of Zhx2.  Similar results were obtained 
from analysis of two independent litters from this AFP genomic transgenic line (data not 
shown).  Thus, while the cDNA transgene does appear to respond to Zhx2, the response 
is not as robust as the endogenous gene, which may suggest that introns are not 
required for Zhx2 regulation, but that they may contribute to the regulatory mechanism.  
However, since expression of the AFP genomic transgene is so low, we can not use it as 
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a positive control for this experiment to know whether the mutated transgene response is 
due to the lack of introns. 
 Because we only obtained one founder animal from each of the transgenes 
containing the AFP250 bp promoter and because the genomic minigene did not express 
well, additional mouse lines expressing the AFP cDNA or genomic minigene under 
control of the 1 kb AFP promoter and AFP E2 were generated (1kb AFP-MG) to test the 
contributions introns make to Zhx2 regulation.  It was anticipated that the 1 kb promoter 
may provide more robust transgene expression.  Five founder mice were obtained from 
each construct and named A-E for the cDNA minigene and G-K for the genomic 
minigene (Figure 3-8).  Founders were crossed to BALB/cJ mice and at least two F1 
mice from each founder were backcrossed to BALB/cJ.  F2 mice were obtained from all 
founders except for the H and I of the AFP genomic minigene line that were sterile.  RNA 
from adult liver of F2 littermate mice from A (Figure 3-9), E (Figure 3-10) and G (Figure 
3-11 and Figure 3-12) founders were analyzed by RT-PCR as described above.  In all 
cases, the endogenous AFP and H19 mRNA was regulated by Zhx2.  However, there 
was variability in expression of AFP transgenes among the lines.  The A2 AFP cDNA-
minigene line did not express the transgene well, based on the very low AFP E3-E15* 
PCR signal (Figure 3-9).  The AFP promoter-regulated transgenes should be repressed 
by four weeks after birth, so to see whether transgene expression in the A2 line might be 
higher at three weeks rather than five weeks after birth, multiple litters were collected at 
various ages.  However, this did not improve detection of this transgene.  In all the other 
cases, E2 AFP cDNA minigene and G1 and G2 AFP genomic minigene, AFP E3-E15* 
PCR signals were detected but unexpectedly, no significant differences in the transgene 
expression was observed in spite of the Zhx2 expression levels. These results indicated 
that the transgenes were not strongly regulated by Zhx2.  Other strategies were utilized 
to analyze the AFP transgene expression, such as Northern blot and S1 nuclease 
(results not shown).  No bands for AFP minigene were visualized in Northern blot from 
total RNA.  Previous studies utilized A+ RNA because AFP is expressed in low levels in 
adult liver.  In general, the AFP transgenes were not well-expressed because about 2.5-
fold more cDNA was required in the PCR reactions to get a signal intensity similar to the 
endogenous AFP gene.  Additionally, low intensity bands corresponding to the AFP 
minigene could be detected by S1 nuclease protection assays but it required over 75 µg 
of total RNA.   Based on the published literature, we fully expected that the AFP genomic 
minigenes would be regulated by Zhx2; it is not clear why this is not the case. 
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Alternative splicing across the AFP gene 
 Based on results described above, we conclude that AFP splicing efficiency is 
dramatically reduced in Zhx2-expressing mice.  To determine whether the presence of 
Zhx2 also caused any alternative splicing of the AFP RNA, we searched for alternatively 
spliced RNAs by RT-PCR using primers that spanned across different AFP exons 
(Figure 3-13A).  Total RNA from two pairs of littermate mice with or without the Flag-
Zhx2 transgene was analyzed.  Under these conditions, AFP E1-E6 and AFP E5-E11 
PCR yielded only the products expected for fully spliced AFP mRNA and these products 
were more abundant in the absence of Zhx2.  The fully spliced mRNA also was 
observed for the AFP E10-E15 PCR, but in this case a weak smaller band of about 430 
bp was also observed.  The E10-E15 region was further analyzed to determine whether 
this band corresponded to an alternatively spliced AFP mRNA (Figure 3-13B).  AFP 
E10-E12, AFP E10-E13 and AFP E11-14 PCRs yielded PCR products with the expected 
sizes for the fully spliced AFP mRNA.  In addition, the AFP E10-E13 PCR also produced 
PCR products with smaller sizes.  These other PCR products may be derived from 
alternatively processed RNAs or they may be artifacts from the PCR amplification.  
However, because the overlapping E10-E12 and E11-E14 PCR reactions did not detect 
any smaller products, it is more likely that the products in E10-E13 are PCR artifacts. 
Also, the abundance of these products was the same in the presence or absence of 
Zhx2.  Thus, we did not pursue this further and conclude that there is no obvious 
alternative splicing mediated by Zhx2.  
 
Nuclear extract preparation from mouse liver and Flag-tagged Zhx2 Immunoprecipitation 
 As discussed previously, Zhx2 regulates AFP expression post-transcriptionally by 
repressing AFP splicing in a promoter dependent manner.  It is possible that Zhx2 may 
interfere with factors that directly or indirectly affect the pre-initiation complex. 
Alternatively, Zhx2 may affect steps of RNAPII elongation that impact post-
transcriptional steps such as RNA splicing, RNA export and/or RNA degradation.  To 
gain more insight into the mechanism of Zhx2 regulation, we intend to identify proteins 
that interact with Zhx2 using a proteomics approach.  This strategy requires co-
purification of Flag-tagged Zhx2 and its interacting proteins from liver nuclear extracts by 
immunoprecipitation with anti-Flag M2 agarose beads, followed by mass spectrometry.  
Transgenic mice that express Flag-tagged Zhx2 in the liver will be used in these 
experiments.  Analysis of liver tissue fractions from Flag-Zhx2 transgenic mice by 
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Western blot demonstrated that the Flag-Zhx2 protein appeared mainly in the chromatin-
associated fraction with the hyperphosphorylated RNAPII (Morford, L., unpublished 
data).  It was also shown that Flag-Zhx2 was expressed at similar levels to the 
endogenous liver Zhx2 in wild-type mice and thus, similar to physiological levels.  
Moreover, Flag-Zhx2 expression in transgenic mice also complemented the Afr1 
phenotype, so the AFP and H19 mRNAs were repressed after birth to the same extent 
as observed in mice that express wild-type Zhx2.  Therefore, livers of these transgenic 
mice are ideal starting material for achieving the co-purification of Flag-Zhx2 and in vivo 
partners for the proteomic study.  
 Because Zhx2 was found to be tightly associated with the chromatin-insoluble 
fraction, the first step was to find a nuclear extract (NE) protocol that allowed recovery of 
Flag-Zhx2 without disrupting protein-protein interactions.  As a control for unspecific 
interactions, littermate mice that did not express the Flag-Zhx2 transgene were included.  
NE were prepared by lysis of purified nuclei obtained from liver of adult mice with or 
without the Flag-Zhx2 transgene.  Lysis of nuclei were performed based on three 
different protocols (Aygun et al., 2008; Dignam et al., 1983; Wuarin and Schibler, 1994) 
and analyzed by Western blot with anti-Flag or anti-Zhx2 antibodies.  The best results 
were obtained using a Dignam-based protocol (Ausubel et al., 1987).  NE preparation 
was optimized using buffers with different concentration of NaCl and KCl.  The best 
Flag-Zhx2 recovery was obtained with 300 mM to 400 mM KCl (results not shown).  
Preparation of NE using this methodology was reproducible and at least half of the Flag-
Zhx2 protein was recovered from the chromatin-insoluble pellet.  Figure 4-14A shows a 
representative Western blot with anti-Zhx2 antibody for one NE preparation using 400 
mM KCl in lysis buffer.  As a positive control, NE from transfected HEK-293 cells with a 
plasmid expressing the Flag-tagged Zhx2 was prepared; Western blot analysis with anti-
Zhx2 detects a band of about 98 KDa, which is the expected size for the Flag-Zhx2 
protein product (Figure 3-14, Lanes 1 and 8).  Similar results were observed with the 
anti-Flag antibody (results not shown).  Analysis by Western blot of the NE prepared 
from the mice that expressed the Flag-Zhx2 transgene (NE+) also showed the 98 KDa 
band recognized by the anti-Zhx2 antibody that is not observed in the NE from littermate 
mice not expressing the transgene.  The next step was optimizing the Flag-Zhx2 
immunoprecipitation using the anti-Flag agarose beads.  As an initial trial, 
immunoprecipitation was performed following the procedure indicated in the instruction 
manual.  NE input and eluate from the immunoprecipitation were analyzed by Western 
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blot as shown in Figure 3-14B.  The band of 98 KDa is observed in the eluate from NE of 
mice that expressed the Flag-Zhx2 (lanes 9 and 10, Figure 3-14B) that is not observed 
in the eluate from NE of transgene-negative mice (lanes 11 and 12, Figure 3-14B), 
indicating that this procedure could specifically pull down the Flag-tagged Zhx2 protein.  
However, one concern was that the buffer used in this immunoprecipitation assay 
contained 1% Triton X-100, which may be too harsh for maintaining some protein-protein 
interactions and is known to interfere with mass spectrometry.  Because NF-YA was 
reported to interact with ZHX2 in HEK-293 cells (Kawata et al., 2003b), it could be used 
as a positive control for protein co-immunoprecipitation.  Other IP trials were performed 
with reduced the detergent concentration, but a precipitate formed during the incubation 
of the NE with the agarose beads, and the eluates showed no specificity.  
 
DISCUSSION 
 The results presented here indicate that Zhx2 dramatically reduces splicing 
efficiency of the AFP transcript.  This is consistent with the reduced steady state AFP 
mRNA levels and increased pre-mRNA accumulation observed in the presence of Zhx2.  
Interestingly, the repression of splicing was observed across all the introns analyzed 
indicating that the effect on splicing is global rather than being specific for certain introns.  
Surprisingly, analysis of the cellular RNA fractions demonstrated that the higher 
accumulation of fully unspliced RNA was observed in the cytoplasmic RNA fraction.  
Moreover, analysis of the cytoplasmic A+ and A- RNA fractions showed that the 
unspliced AFP RNA is mainly in the A- RNA fraction.  This result suggested that the 
unspliced AFP RNA found in the cytoplasm is not polyadenylated or that the poly-A tail is 
too short to bind to the oligo-dT column.  Therefore, the unprocessed AFP RNA is 
escaping the nuclear surveillance mechanisms and being exported to the cytoplasm 
where it is likely deadenylated.  Although these findings were unexpected, there are 
some reports in the literature indicating that pre-mRNA could leak into the cytoplasm and 
even be translated when splicing is repressed by small molecules or mutations that 
target spliceosome components (Kaida et al., 2007; Legrain and Rosbash, 1989; Lo et 
al., 2007; O'Brien et al., 2008).  Thus, the presence of unspliced AFP transcripts in the 
cytoplasm is consistent with the idea that Zhx2 globally represses splicing of AFP pre-
mRNA.   
 Zhx2 also decreased mRNA accumulation of other two target genes, H19 and 
Gpc3, and at least H19 was shown by nuclear run-on to be transcribed at the same rate 
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in the presence or absence of Zhx2.  It may be expected that Zhx2 will affect expression 
of these genes by a similar mechanism.  Therefore, we investigated whether splicing of 
these genes was repressed similarly to that observed for AFP gene.  Radiolabeled RT-
PCR reactions were performed to detect unspliced H19 RNA in the cytoplasmic RNA 
fraction to increase the sensitivity of the assay compared to standard RT-PCR.  With 
these assays, a lower accumulation of PCR product corresponding to the mRNA was 
observed in the presence of Zhx2, but PCR products corresponding to unspliced RNA 
were not detected across the multiple exon-exon regions of the H19 gene analyzed 
(Figure 3-5).  One possible explanation for this result is that Zhx2 inhibits H19 splicing 
but unprocessed H19 RNA is rapidly turned over in the nucleus, as normally occurs with 
aberrant spliced transcripts.  Additional experiments should be done analyzing nuclear 
RNA and primers that target exon-intron or intron-intron regions as another way to 
determine whether there are differences in accumulation of unspliced H19 RNA in the 
presence of Zhx2.  In the case of Gpc3, there was a lower accumulation of spliced RNA 
in presence of Zhx2 in both nuclear and cytoplasmic RNA fractions, but the difference 
was not as marked as that observed in the H19 and AFP genes.  Unspliced Gpc3 RNA 
product was not detected in the cytoplasmic fraction and no remarkable difference was 
observed in the nuclear soluble fraction between the presence or absence of Zhx2.  The 
fact that Gpc3 pre-mRNA is not detected in the cytoplasm suggested that any unspliced 
Gpc3 transcripts must be rapidly processed or degraded.  Together, these splicing 
results raise the question of what accounts for the unexpected stability of unprocessed 
AFP RNA compared to the transcripts of other Zhx2 target genes?  In fact, it is perhaps 
fortunate that unprocessed AFP RNA is stabilized so that it can be detected as it 
provides important clues to the Zhx2 regulatory mechanism.  It is not clear at this point 
whether Zhx2 affects splicing of target genes in the same way as the AFP gene or 
whether other post-transcriptional mechanism may be involved.  Further analysis of the 
nascent RNA splicing, in chromatin-associated RNA fractions, may provide information 
about Zhx2 regulation of the H19 and Gpc3 genes. 
 
Analysis of AFP intron requirement for Zhx2 regulation in transgenic mice 
 Because Zhx2 affected the splicing of AFP pre-mRNA, whether AFP introns were 
required for Zhx2 mediated regulation also was investigated.  For this purpose 
transgenic mice that expressed AFP minigenes in its cDNA or genomic (intron 
containing) forms were generated.  These minigenes were based on other constructs 
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that were reported to be repressed after birth and responsive to Zhx2.  The cDNA AFP 
minigene driven by 250 bp AFP promoter was regulated in response to Zhx2 but the 
fold-change between mice that did or did not express Zhx2 was smaller than the 
difference in the endogenous AFP and H19 genes.  However, the genomic AFP 
minigene driven by the 250 bp AFP promoter was not expressed well in the transgenic 
mice and therefore, its regulation by Zhx2 could not be assessed.  Transgenic mice that 
expressed the cDNA or the genomic AFP minigenes driven by the 1 kb AFP 
repressor/promoter region were also generated.  Surprisingly, these AFP minigenes 
were not strongly regulated in response to Zhx2 in the F2 offspring from E (cDNA) and G 
(genomic) founders, while the cDNA AFP minigene was not expressed well in the F2 
offspring from the A founder.  In contrast, endogenous AFP and H19 genes were 
regulated by Zhx2 as expected in all the cases.  No obvious Zhx2 regulation was 
observed either by S1 analysis or by semi-quantitative RT-PCR analysis.  F2 littermate 
liver RNA from three other cDNA transgene founders and two other genomic AFP 
transgene founders remain to be analyzed.  At this point, why these minigenes are not 
regulated in response to Zhx2 is not known. 
 
Mechanism of AFP splicing repression by Zhx2 
 Transport of pre-mRNA to the cytoplasm has been observed by interfering with 
early steps in the spliceosome assembly.  This includes mutations in U1 snRNA or 
mutations in either the 5’ splice site or the branchpoint sequence (Legrain and Rosbash, 
1989).  Accumulation of pre-mRNAs in the cytoplasm also was induced with 
spliceostatin A, an inhibitor of splicing, which target the SF3b subcomplex of the U2 
snRNP (Kaida et al., 2007).  Because SF3b interacts with components of the retention 
and splicing (RES) complex in yeast, it was suggested that SF3b is involved in 
recognizing intron-containing transcripts for nuclear retention.  Based on these studies it 
can be proposed that Zhx2 might interfere with recruitment of one or more of the trans-
acting factors involved in early spliceosome assembly and subsequently, avoid the 
nuclear retention and degradation.  If this is the mechanism by which Zhx2 regulates its 
target genes, it would require introns for regulation.  Because preliminary results suggest 
that a cDNA transgene is at least partially regulated, it is possible that introns contribute 
to the Zhx2 regulation but they can not be required. 
 Only a few other cases of gene regulation by intron retention have been 
observed, one being in the posttranscriptional regulation of the TNF gene expression 
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(Yang et al., 1998).  TNF pre-mRNA was found to accumulate in the nucleus in naïve T 
cells.  Upon T cell activation, TNF pre-mRNA splicing was quickly induced, resulting in 
high levels of TNF mRNA and protein.  The mechanism by which TNF pre-mRNA 
splicing is repressed in naïve T cells and then induced soon after T cell activation, 
remains unknown.  However, it was suggested that a negative regulator may block TNF 
pre-mRNA processing and be released upon T cell activation to allow proper TNF pre-
mRNA processing.  Another example of regulation through intron retention is observed 
in the primary response genes (PRGs), which produce full-length transcripts, but no 
mRNA, in unstimulated macrophage (Hargreaves, 2009).  Promoters of PRGs are pre-
associated with serine 5-phosphorylated RNAPII prior LPS stimulation, allowing 
transcription of full-length pre-mRNA that are quickly degraded rather than spliced.  
Uninduced promoters do not recruit pTEF-b to phosphorylate RNAPII on serine 2, which 
is required for co-transcriptional RNA processing, because the promoters are bound by 
co-repressor molecules.   Upon LPS stimulation, pTEF-b is recruited through the adaptor 
protein Brd4, inducing RNAPII phosphorylation at serine 2 and generation of mature 
RNA.   
 By analogy to these situations, it is possible that Zhx2 interferes with recruitment 
of factors involved in coupling transcription with RNA processing factors (Figure 3-15), 
for example by blocking RNAPII phosphorylation.  This would result in AFP pre-mRNA 
splicing inhibition and concomitant reduction of AFP mRNA.  These factors may also 
impact stability of the AFP pre-mRNA and avoid nuclear retention.  Therefore, AFP pre-
mRNA could escape from the nuclear surveillance mechanisms and be transported to 
the cytoplasm.  Insight into the mechanism of Zhx2 regulation could be obtained by 
proteomic analysis of Zhx2-interacting proteins. 
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Figure 3-1.  Scheme of PCR reactions performed for analysis of AFP splicing.  
Diagram of the 15-exon AFP structural gene and location of the PCR primer pairs 
utilized for AFP splicing analysis. B1 is a repetitive element within intron 1 known to be 
transcribed by RNA polymerase III from the opposite strand to that encoding AFP RNA 
(Godbout et al., 1986). AFP E2-E3, primers E2E3-F/E2E3-R; AFP I1-I2, primers i1-F/i2-
R; AFP E2-I2, primers E2E3-F /i2-R; AFP I2-I3, primers i2-F/i3-R; AFP E5-E6, primers 
E5-F/E5E6-R; AFP E5-I5, primers E5-F/i5-R; AFP E14-E15, primers Afp3’-F/Afp3’-R1; 
AFP E14-pA, primers Afp3’-F/Afp3’-R2; AFP I9-I10, primers i9-F/i10-R; AFP I10-I11, 
primers i10-F/ i11-R; AFP E10-E11, primers E10E11-F/ E10E11-R, AFP E12-E13, 
primers E12E13-FB/E12E13-RB, AFP I12-I12, primers nest12-13BF/nest12-13BR.  All 
primer sequences are listed in Table 2-3. 
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Figure 3-2. AFP pre-mRNA splicing is repressed in the presence of Zhx2.  RT-PCR 
reactions using total RNA extracted from adult liver of two independent sets of littermate 
mice with (Zhx2+) or without (Zhx2-) the Flag-Zhx2 transgene.  cDNA was made from 1 
µg of total RNA and PCR reactions were performed with 1 to 5 µl of cDNA diluted 1:5. 
The expected sizes of the PCR products are shown on the left; a diagram of the location 
of each primer pair is shown on the right.  PCR products were collected at different 
cycles to ensure a linear PCR amplification range (only one set of reactions is shown).  
rpL30 is used as loading control (23 cycles); AFP E2-E3, AFP I1-I2, AFP E2-I2, AFP I2-
I3, AFP E5-E6, AFP E5-I5, AFP E14-E15, AFP E14-pA (33 cycles); AFP I9-I10, AFP 
I10-I11 (30 cycles); AFP E10-E11, AFP E12-E13, AFP I12-I12 (31 cycles).  To check for 
DNA contamination, negative controls without RT enzyme were performed followed by 
PCR amplification with primers for L30 and AFP E10-E11 as described above. 
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Figure 3-3.  Splicing analysis of AFP transcripts in cellular RNA fractions from 
liver of littermate mice with or without the Flag-Zhx2 transgene.  cDNA was made 
from 1 µg of the indicated RNA fraction.  PCR reactions were performed with 1 to 5 µl of 
cDNA diluted 1:5 from cytoplasmic RNA fraction and undiluted cDNA from nuclear 
soluble or insoluble RNA fractions.  PCR products were collected at different cycles to 
ensure a linear PCR amplification range (only one set of reactions is shown).  rpL30 
(L30R/L30F2) was used as loading control (27 cycles); AFP E10/E11 PCR (E10E11-F/ 
E10E11-R; 31 cycles), β actin PCR (B-ActF/ B-ActR; 26 cycles cytoplasmic fraction and 
29 cycles nuclear soluble and insoluble fractions), U6 PCR (U6F/U6R; 26 cycles).  U6 
PCRs were performed from cDNAs prepared with 1 µg of RNA fractions without dilution, 
so that undetectable levels of U6 in the cytoplasmic fractions was not due to a dilution 
factor.  U6 PCR for nuclear soluble fractions were performed under same conditions but 
at 27 cycles.  The AFP and β actin lanes shown were assembled from non-adjacent 
lanes of the same gel.  
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Figure 3-4.  Splicing analysis of cytoplasmic A+ and A- RNA fractions.  Liver 
cytoplasmic RNA from littermate mice with or without the Flag-Zhx2 transgene were 
fractionated into A+ and A- RNA fractions using oligo-dT columns.  cDNA was made 
using 1 µg of A- RNA fraction or 12 ng of A+ RNA fraction with random hexamers.  PCR 
reactions were performed with 0.5 µl of cDNA for L30 PCR or 2 µl of cDNA for AFP 
E10/E11 PCR.  PCR products were collected at different cycles to ensure a linear PCR 
amplification range (only one set of reactions is shown).  rpL30 (primers L30R/L30F2) 
were used as loading control (23 cycles); AFP E10/E11 PCR, primers E10E11-F/ 
E10E11-R (31 cycles); AFP E14/E15 PCR, primers E14E15-F/Afp3’-R1 (33 cycles).  All 
primer sequences are listed in Table 2-3. 
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Figure 3-5. Splicing analysis of Gpc3 RNA in cytoplasmic and nuclear soluble RNA 
liver fractions.  RNA was extracted from cytoplasmic and nuclear soluble fractions of 
liver tissue obtained from littermate mice with or without the Flag-Zhx2 transgene.  cDNA 
was made with 1 µg of the indicated RNA fractions.  PCR reactions performed with 1-2 
µl of cDNA diluted 1:5 from the cytoplasmic RNA fraction and cDNA undiluted from the 
nuclear soluble fractions.  PCR products were collected at different cycles to ensure a 
linear PCR amplification range.  rpL30 (L30R/L30F2) was used as loading control (22 
cycles); Gpc3 E4/E6 PCR (Gpc3URT/Gpc3LRT, 33 cycles); Gpc3 I5/E6 (Gpc3 U-
2/Gpc3LRT, 32 cycles); Gpc3 E7/E8 PCR (Gpc3E7-U/Gpc3E8-L, 33 cycles); H19 PCR 
Exons 4 and 5 (S-H19/AS-H19, 30 cycles). 
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Figure 3-6. Splicing analysis of H19 RNA in cytoplasmic RNA liver fractions.  1 µg 
of cytoplasmic RNA fractions from littermate mice with or without the Flag-Zhx2 
transgene were used for cDNA preparation with random hexamers.  PCR amplification 
was performed with 5 µl of cDNA diluted 1:5 and primers targeting different exon-exon 
regions of H19 gene represented in (A).  All PCR reactions were carried out for 29 
cycles at 55 ºC with the reverse primer radiolabeled with polynucleotide kinase (PNK) 
and [γ-32P]-ATP.  PCR products were analyzed on 6% or 8% denaturing polyacrylamide 
gels and detected by phosphorimaging (B). Boxes indicated PCR products 
corresponding to spliced mRNA. “*” indicates the PCR product from genomic DNA used 
as positive control (C) for expected size of the unspliced RNA.  From left to right: PCR 
E1-E2, primers E1E5H19-F/ H19Ex2-L; PCR E1-E3, primers E1E5H19-F/H19Ex3-L3; 
PCR E2-E3, primers H19Ex2-U/H19Ex3-L2; PCR E2-E3, primers H19Ex2-U/H19Ex3-
L3; PCR E2-E5, primers H19Ex2-U/E1E5H19-R. 
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Figure 3-7. Splicing regulation by Zhx2 of AFP minigenes driven by the 250 bp 
AFP promoter region.  (A) AFP minigenes used in previous studies contained the 
albumin enhancer and 1kb promoter to drive expression of a short version of the AFP 
gene where the internal sequence from exon 4 through exon 13 was deleted (Vacher et 
al., 1992).  The second construct contains the AFP enhancer II and AFP 250 bp 
promoter to drive expression of the class I MHC Dd gene (Peyton et al., 2000a).  Both 
construct were repressed after birth and responsive to Zhx2 regulation.  Based on these 
transgenes, the AFP minigenes in the genomic or cDNA forms were designed.  These 
AFP genomic and cDNA minigenes were driven by the AFP enhancer II and AFP 250 bp 
promoter.  Additionally, an 18 bp sequence was inserted within exon 15 (*) to detect the 
transgene by RT-PCR.  To study regulation of transgene by Zhx2, at least two offspring 
from each founder were backcrossed to BALB/cJ.  RNA was extracted from livers of 3-4 
week old F2 littermate mice and analyzed by RT-PCR (B).  cDNA was prepared from 1 
µg of RNA and 1-2 µl of 1:5 diluted cDNA was used for PCR amplification.  AFP 
transgene, AFP E3-E15 PCR, primers E3F/E15R (2 µL RT 1:5 diluted, 33 cycles); 
endogenous AFP and H19 expression was analyzed as control for Zhx2 regulation: AFP 
E10-E11 PCR, primers E10E11-F/ E10E11-R (2 µL RT 1:5 diluted, 31 cycles).  H19 
PCR, primers S-H19/AS-H19 (1 µL RT 1:5 diluted, 28 cycles cDNA transgene and 29 
cycles genomic transgene samples).  rpL30 was used as loading control, primers 
L30R/L30F2 (1 µL RT 1:5 diluted, 23 cycles cDNA transgene and 22 cycles genomic 
transgene samples).   
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Figure 3-8. Scheme of transgenic founder mice expressing the cDNA and genomic 
AFP minigenes driven by the 1kb AFP promoter region. (A) AFP cDNA and genomic 
minigene as described in figure 4-7 (A) but driven by the AFP enhancer II and AFP 1kb 
promoter.  (B) Founders expressing the AFP cDNA (A-E) and genomic (G-K) minigenes.  
Founder animals were crossed to BALB/cJ mice.  To study regulation of the transgene 
by Zhx2, at least two offspring from each founder were backcrossed to BALB/cJ.  The 
numbers indicate the number of litters harvested for RNA analysis.  The H and I 
founders were sterile and K1 did not segregated the transgene; these are indicated by 
an “X”.   Not all of the litters have been analyzed yet. 
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Figure 3-9. Analysis of splicing regulation by Zhx2 of the AFP cDNA minigene 
driven by the 1kb AFP promoter region, line A2.  1 µg of liver RNA from 3-5 week old 
littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was used 
for PCR amplification.  AFP transgene expression was determined by AFP E3-E15 PCR 
(primers E3F/E15R, 5 µL RT 1:5 dilution and 33 cycles) or AFP E14-E15 (primers 
E14E15-F/E15R, 5 µL RT 1:5 dilution and 31 cycles); endogenous AFP and H19 
expression was analyzed as controls for Zhx2 regulation by primer targeting the AFP 
E10-E11 (E10E11-F/E10E11-R, 2 µL RT 1:5 dilution and 31 cycles) and the H19 gene 
(S-H19/AS-H19, 2 µL RT 1:5 dilution and 30 cycles). Zhx2 expression levels were 
determined with primers Z2HD1-F/ Z2HD1-R (3 µL RT 1:5 dilution and 30 cycles). rpL30 
(L30R/L30F2, 1 µL RT 1:5 dilution and 25 cycles) was used as loading control. The 
numbers below the figure are the sample tracking numbers of the animals analyzed. 
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Figure 3-10. Analysis of splicing regulation by Zhx2 of AFP cDNA minigene driven 
by the 1kb AFP promoter region, line E2.  1 µg of liver RNA from 5 weeks littermate 
mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was used for PCR 
amplification.  AFP transgene expression was determined by AFP E3-E15 PCR (primers 
E3F/E15R, 5 µL RT 1:5 dilution and 31 cycles) or AFP E14-E15 (primers E14E15-
F/E15R, 5 µL RT 1:5 dilution and 31 cycles); endogenous AFP and H19 expression was 
analyzed as controls for Zhx2 regulation by primers targeting AFP E10-E11 (E10E11-
F/E10E11-R, 2 µL RT 1:5 dilution and 31 cycles) and the H19 gene (S-H19/AS-H19, 2 
µL RT 1:5 dilution and 30 cycles). rpL30 (L30R/L30F2, 1 µL RT 1:5 dilution and 25 
cycles) was used as loading control.  The numbers below the figure are the sample 
tracking numbers of the animals analyzed. 
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Figure 3-11. Analysis of splicing regulation by Zhx2 of AFP genomic minigene 
driven by the 1kb AFP promoter region, line G1.  1 µg of liver RNA from 3 or 5 week 
old littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was 
used for PCR amplification.  AFP transgene expression was determined by AFP E3-E15 
PCR (primers E3F/E15R, 5 µL RT 1:5 dilution, 30 cycles samples 127-130 and 31 cycles 
samples 46-51) or AFP E14-E15 (primers E14E15-F/E15R, 5 µL RT 1:5 dilution, 31 
cycles); 490 bp band in AFP E3-E15 PCR correspond to the expected size of RNA 
transcripts with intron 14 retention. Endogenous AFP and H19 expression was analyzed 
as controls for Zhx2 regulation by primers targeting AFP E10-E11 (E10E11-F/E10E11-R, 
2 µL RT 1:5 dilution, 31 cycles) and the H19 gene (S-H19/AS-H19, 2 µL RT 1:5 dilution, 
30 cycles).  Zhx2 expression levels were determined with primers Z2HD1-F/ Z2HD1-R (3 
µL RT 1:5 dilution, 31 cycles samples 127-130 and 33 cycles samples 46-51).  rpL30 
(L30R/L30F2, 1 µL RT 1:5 dilution, 25 cycles) was used as loading control. The numbers 
below the figure are the sample tracking numbers of the animals analyzed. 
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Figure 3-12. Analysis of splicing regulation by Zhx2 of AFP genomic minigene 
driven by the 1kb AFP promoter region, line G2.  1 µg of liver RNA from 3 or 5 week 
old littermate mice was used for cDNA preparation and 1-5 µl of 1:5 diluted cDNA was 
used for PCR amplification.  AFP transgene expression was determined by AFP E3-E15 
PCR (primers E3F/E15R, 5 µL RT 1:5 dilution, 30 cycles) or AFP E14-E15 (primers 
E14E15-F/E15R, 5 µL RT 1:5 dilution, 31 cycles); endogenous AFP and H19 expression 
was analyzed as controls for Zhx2 regulation by primers targeting AFP E10-E11 
(E10E11-F/E10E11-R, 2 µL RT 1:5 dilution, 31 cycles) and the H19 gene (S-H19/AS-
H19, 2 µL RT 1:5 dilution, 30 cycles).  Zhx2 expression levels were determined with 
primers Z2HD1-F/ Z2HD1-R (3 µL RT 1:5 dilution, 31 cycles). rpL30 (L30R/L30F2, 1 µL 
RT 1:5 dilution, 25 cycles) was used as loading control. The numbers below the figure 
are the sample tracking numbers of the animals analyzed. 
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Figure 3-13.  Analysis of alternative splicing across the AFP gene.  cDNA was 
made from 1 µg of total RNA from liver of two sets of littermate mice with or without the 
Flag-Zhx2 transgene.  (A) One to five µl of 1:5 diluted cDNA was used for PCR 
amplification of the AFP gene regions indicated on the left.  The expected sizes of the 
PCR products corresponding to the fully spliced mRNAs are shown on the left. To further 
examine the ~430 bp product in the AFP E10-E15 reaction, the additional PCR reactions 
in (B) were performed.  On the right are shown the predicted PCR product sizes for 
alternatively spliced RNAs if specific exons are skipped (identified by Δ).  rpL30 (primers 
L30R/L30F2) was used as a loading control and is shown in Figure 4-2.  PCR E1-E6, 
primers E1F and E5E6R; PCR E5-E11, primers E5-F and E10E11-R; PCR E10-E15, 
primers E10E11-F and E13E15-R; PCR E10-E12, primers E10E11-F and AFPE12A; 
PCR E10-E13, primers E10E11-F and E12E13-RB; PCR E11-E14, primers E14R and 
E11E12F. 
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Figure 3-14.  Nuclear extract preparation from liver of Flag-Zhx2 transgenic mice 
and anti-Flag-epitope immunoprecipitation.  (A) Total nuclei (lanes 2 and 5, 10 µl), 
nuclear extract (lanes 3 and 6, 20 µl) and the insoluble pellet (lanes 4 and 7, 20 µl) 
fractions from liver of mice with (+) or without (-) the Flag-Zhx2 transgene were analyzed 
by Western blot with a rabbit polyclonal anti-Zhx2 antibody.  (B) 100 µg of nuclear 
extracts from an independent preparation to that shown in (A) was used for 
immunoprecipitation using the M2 anti-flag agarose (Sigma).  NE input (lanes 9 and 11, 
50 µg) and respective eluates (lanes 10, and 12).  NE from transiently transfected 
HEK293 cells were used as positive control and molecular size reference for Flag-Zhx2 
(lanes 1 and 8, 2.5 µg total protein per line). 
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Figure 3-15. Proposed model for Zhx2-mediated splicing repression of AFP gene.  
(A) Before birth levels of Zhx2 are low consistent with high expression of AFP during 
fetal development. In the absence of Zhx2 expression, AFP RNA transcripts are fully 
spliced resulting in high levels of mRNA accumulation and AFP protein expression. (B) 
After birth levels of Zhx2 increase and AFP expression is repressed. Our data suggest 
that Zhx2 interferes with normal splicing so that AFP mRNA levels are low. Possible 
mechanisms include blocking recruitment of splicing factors or altering RNA polymerase 
II phosphorylation. Zhx2 may also be acting indirectly.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright  Lilia M. Turcios 2011 
 73 
CHAPTER IV 
TRANSCRIPTION TERMINATION IN THE Cµ GENE 
 
INTRODUCTION 
 Termination of RNAPII transcription occurs at variable distances downstream 
from functional cleavage-polyadenylation [poly(A)] signals to recycle RNAPII complexes 
and prevent read-through transcription into adjoining genes.  Termination has also been 
shown to enhance protein and mRNA expression from genes transiently transfected into 
cells (West and Proudfoot, 2009).  While a functional poly(A) signal is essential for 
termination, additional sequences downstream from poly(A) signals are also required in 
some genes (Richard and Manley, 2009).  For example, RNAPII pause sites have been 
identified downstream of multiple poly(A) signals (Ashfield et al., 1991; Enriquez-Harris 
et al., 1991; Gromak et al., 2006; Peterson et al., 2002).  Also, an element positioned 
between 800 and 1600 nt downstream from the human β-globin poly(A) signal, which 
was shown to have co-transcriptional cleavage (CoTC) activity, is required for β-globin 
gene termination (Dye and Proudfoot, 2001).  This CoTC cleavage element also 
functions to direct transcription termination when it is moved to a position about 200 nt 
from the poly(A) signal (Dye and Proudfoot, 2001).  The β-globin CoTC element can also 
be replaced by the well-characterized MAZ4 RNAPII pause element or a pause element 
found downstream from the human β-actin gene (Gromak et al., 2006).  The human ε- 
globin gene and the mouse serum albumin gene were also found to have a termination 
region that contained CoTC activity (Dye and Proudfoot, 2001; West et al., 2006), but 
CoTC activity is not found in all terminator regions examined (Gromak et al., 2006; Plant 
et al., 2005). 
 The current model for how RNAPII terminates downstream from protein-coding 
genes is a hybrid version of two original models (Bentley, 2002).  Transcription through a 
poly(A) signal seems to make the RNAPII complex “termination competent”; a functional 
poly(A) signal is always required.  Once the nascent transcript is cleaved, either by the 
cleavage-polyadenylation machinery acting on the poly(A) signal or by a CoTC element, 
the exposed 5’ end of the 3’ product becomes an entry point for an exonuclease to 
degrade the downstream RNA.  This is required, but not sufficient, for RNAPII to release 
the template DNA (West et al., 2008).  RNAPII is often seen to pause downstream from 
poly(A) signals, in some cases, it is due to the presence of specific sequences (Dye and 
Proudfoot, 2001; Fong and Bentley, 2001; Peterson et al., 2002) and in others, the 
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pausing is directed by the poly(A) signal itself (Orozco et al., 2002).  While this model for 
the events that occur after RNAPII transcribes a poly(A) signal provides a framework for 
understanding the termination process, not all the details of this process have been 
established.  In addition, it is not yet clear how termination downstream of more complex 
transcription units, such as genes containing multiple poly(A) signals, is regulated or 
whether termination is a part of the regulatory choice among multiple poly(A) signals. 
 The immunoglobulin M (µ) gene is a complex transcription unit that contains two 
poly(A) signals, µs and µm. The upstream µs poly(A) signal is within the Cµ4-M1 intron 
and the relative strengths of the competing cleavage-polyadenylation and splicing 
reactions is a major determinant of which mRNAs are produced.  In B cells, the µs 
poly(A) signal is recognized less efficiently so more spliced µm mRNA is made whereas 
in plasma cells, use of the µs poly(A) signal predominates over Cµ4-M1 splicing, 
resulting in mostly µs mRNA being produced.  Transcription termination in the µ gene 
has been well-studied and was shown to change during B lymphocyte development; the 
transcription unit is gradually foreshortened as B cells mature to plasma cells (Kelley and 
Perry, 1986; Peterson, 2007; Weiss et al., 1989; Yuan and Tucker, 1984).  In B cells, 
transcription terminates far downstream of the distal µm poly(A) signal while in plasma 
cells, transcription terminates in the vicinity of this µm poly(A) signal, about 2 kb 
downstream from the upstream µs poly(A) signal.  It is possible that the developmental 
differences in the extent of transcription may be due to changes in the use of the poly(A) 
signals in this gene.  A RNAPII pause element was identified in the region 50 – 200 nt 
downstream of the µs poly(A) signal (Peterson et al., 2002).  When this element was 
deleted, the amount of RNA cleaved and polyadenylated at the µs poly(A) site 
decreased while the RNA spliced between the Cµ4 and M1 exons was increased, in 
both B cells and plasma cells.  Thus, this element contributes to the balance in 
efficiencies between the competing splice and cleavage-polyadenylation reactions, but 
does not seem to be directly involved in the RNA processing regulation.  This pause 
element can be replaced by pause elements found downstream of other poly(A) signals 
(Peterson et al., 2002) and can cause RNAPII pausing in heterologous contexts 
(Peterson et al., 2002; Robson-Dixon and Garcia-Blanco, 2004).  Whether any co-
transcriptional cleavage activity exists within the µ gene locus that may contribute to the 
developmental termination has not been investigated. 
 Much of our knowledge of transcription termination and how CoTC and/or pause 
elements are involved in this process have been established using a model substrate, 
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where the human β-globin gene driven by the highly active HIV promoter was transiently 
transfected into HeLa cells.  While this model system has discovered mechanistic details 
that would have been difficult to find in less robustly expressed genes, it is an artificial 
system, which raises the question of how broadly the details apply to natural 
transcription units.  Thus, to examine the effects of the CoTC element in another context 
and determine how it affects transcription termination and alternative RNA processing 
choices of a more complex transcription unit, we have introduced the CoTC element into 
the well-studied mouse µ gene and explored the effects in stably transfected lymphocyte 
cell lines.  While the β-globin CoTC element has been shown to promote termination 
downstream from poly(A) signals, it did not disrupt splicing when placed within the 850 nt 
β globin second intron (Dye et al., 2006).  However, placement of the β-globin CoTC 
element in the 1862 nt Cµ4-M1 intron may have several possible outcomes.  It was 
possible that splicing of the longer Cµ4-M1 intron would be disrupted, depending on how 
fast cleavage occurs, relative to transcription of the complete intron.  On the other hand, 
CoTC elements and pause sites were functionally interchangeable downstream from the 
β globin poly(A) signal (Gromak et al., 2006).  Therefore, it was possible that the CoTC 
element would be able to replace the activity of the µ pause element, or since pause and 
CoTC elements act in different ways, it was also possible that these elements would not 
be interchangeable in the µ gene context.  Thus, to examine how the CoTC element will 
affect the delicate balance between the competing poly(A) signal and splice reaction, we 
placed the CoTC element in several locations within the Cµ4-M1 intron, in the presence 
or absence of the µ pause element.  It is known that changes in the length of the Cµ4-
M1 intron affect the pA/splice mRNA ratio, so expression of the constructs containing the 
CoTC element were compared to constructs in which the Cµ4-M1 intron size was 
modified with fragments not known to contain pause or CoTC activity.  We find that the 
CoTC located within the Cµ4-M1 intron near, but not far, from the µs poly(A) signal 
affected µs/µm mRNA expression.  In addition, we find no evidence for natural CoTC 
activity in the µ gene. 
 
RESULTS 
The β globin CoTC at a distal position does not affect µ mRNA processing 
To examine the how a CoTC element may effect µs/µm processing, we placed 
the 800-bp β globin CoTC element at the KpnI site within the Cµ4-M1 intron (1200 bp 
from the µs poly(A) and 500 nt upstream from the M1 3’ splice site), in the context of an 
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intact µ gene, containing the Ig promoter and enhancer, a rearranged VDJ region, the 
complete IgM constant region and about 2 kb of sequence downstream of the µm 
poly(A) signal ((Peterson and Perry, 1989); Cµ/CoTC (+), Figure 4-1).  Because the 
CoTC and pause elements had similar effects on transcription termination in other 
contexts (Gromak et al., 2006), we also inserted the CoTC into the µ gene from which 
the pause had been deleted (∆NH/CoTC(+), Fig ure 4-1).   We have shown previously 
that the size of the Cµ4-M1 intron affects the µs/µm mRNA expression ratio; a shorter 
intron decreases the pA/splice ratio while a longer intron increases it (Peterson, 1992; 
Peterson, 1994b; Peterson et al., 1994; Peterson and Perry, 1986, 1989; Seipelt and 
Peterson, 1995). Thus, to detect any effects specific to the CoTC rather than just 
changes to the intron size, we made multiple intron size control constructs.  In one, we 
inserted the 800 bp CoTC into the Cµ4-M1 intron from which an 800 bp fragment had 
been deleted (∆AR/CoTC(+), Figure 4-1), which places the CoTC element about 400 nt 
downstream of the µs poly(A) signal.  We also isolated CoTC element insertions in the 
opposite, presumably inactive, orientation for these three constructs (CoTC(-) versions, 
Figure 4-1).  We also used other constructs containing various intron sizes described in 
previous studies as controls (Table 2-1, Figure 4-1).  These include ∆NR, containing a 
351 bp deletion between the NcoI and EcoRV sites; ∆AN, containing a 446 bp deletion 
between the AccI and NcoI sites; ∆AR, containing a 797 bp deletion between the AccI 
and EcoRV sites; ∆AR/pBR403 and ∆AR/rpI900 containing a 403 bp or 900 bp fragment 
inserted at the KpnI site of ∆AR; and Cµ/rpI900, containing the 900 bp fragment inserted 
at the KpnI site of Cµ (Peterson and Perry, 1986).  All of these genes were stably 
introduced into M12 B cells and S194 plasma cells, both of which do not express their 
endogenous µ genes, and total RNA was analyzed by S1 nuclease mapping to measure 
the relative expression of µs (pA) and µm (splice) mRNA (Figure 4-2).  Since previous 
placement of the CoTC into the β-globin intron did not affect expression, it was possible 
that it would have no effect on µ gene expression.  However, because this intron is 
involved in the cis-competition with the µs poly(A) signal, it was possible that the CoTC 
could affect the balance between these reactions; this cis-competition is sensitive so that 
minor changes can be detected.  Also, since this intron contains a pause element, we 
could determine whether the CoTC element was able to replace this pause element as it 
could in other genes. 
 Predictably, because inserting the CoTC element lengthened the Cµ4-M1 intron, 
the pA/splice expression ratio increased for all CoTC(+) constructs relative to their 
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starting constructs and this was observed in both B cells and plasma cells [Cµ vs. 
Cµ/CoTC(+), ∆NH vs. ∆NH/CoTC(+) and ∆AR vs. ∆AR/CoTC(+), Figures 4-1 and 4-2].  
The one exception was Cµ and Cµ/CoTC in plasma cells, which expressed similarly high 
pA/splice mRNA ratios.  To determine whether the CoTC element could replace the 
pause element, we compared the Cµ and ∆NH constructs to these genes that contain 
the inserted CoTC element (Figures 4-1 and 4-2).  In B cells, the pA/splice ratio of ∆NH 
is about 3-fold lower than Cµ.  A similar difference in the pA/splice ratio is also seen 
between Cµ/CoTC(+) and ∆NH/CoTC(+).  This suggests the CoTC is not able to replace 
the activity of the pause site when inserted at this location about 1 kb downstream from 
where the pause site is normally located.  It is interesting to note that various pause sites 
inserted at this KpnI site also did not replace the activity lost by deletion of the NH pause 
element (Peterson et al., 2002).  
 To better visualize the expression changes caused by the CoTC elements, 
relative to the intron size controls, we plotted intron size vs the pA/splice expression ratio 
(Figure 4-3).  The ∆NH constructs, which lack the pause element have, by definition, an 
effect that is greater than the size of the element and thus have not been included in this 
plot.  The trend of the greater intron size causing an increase in the pA/splice ratio can 
clearly be seen from the size control constructs.  While there is some scatter from a 
straight line, which indicates that primary sequence or RNA structure also contributes to 
the pA/splice ratio, the strong trend indicates that intron size is a major determinant of 
the expression ratio.  In general, the CoTC(+) constructs fall within the range expected 
based on intron size, rather than having an increased pA/splice ratio that would indicate 
a specific effect of the CoTC element.  The constructs ∆AR/CoTC(+), ∆AR/rpI900 and 
Cµ, which all have Cµ4-M1 introns of a similar size, all have similar expression ratios in 
B cells (Figures 4-1 and 4-2), which is also consistent with the CoTC element not 
affecting pA/splice ratio from the KpnI site location in the Cµ4-M1 intron. 
 Curiously, all the constructs with the CoTC element in the opposite orientation 
had much lower expression ratios than expected based on the intron size (Figure 4-1, 
Figure 4-2 and “x” in plots in Figure 4-3).  It appears that the CoTC(-) fragment contains 
activity that greatly enhances Cµ4-M1 splicing relative to cleavage-polyadenylation at 
the µs poly(A) signal.  Because expression is measured by S1 nuclease mapping, which 
would not detect any aberrant splicing caused by this fragment, we performed multiple 
RT-PCR reactions, as well as 3’ RACE, to determine whether the Cµ4 5’ splice site was 
being spliced to a new 3’ splice junction.  However, only the expected products were 
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detected (data not shown). We propose that the enhanced splicing activity may be due 
to a fortuitous splice enhancer sequence introduced with the anti-sense β-globin CoTC, 
but we did not test this hypothesis further. 
 Because the expression data indicated that the CoTC element did not affect Ig 
expression, we needed to determine whether this was because the CoTC element was 
not being cleaved in the µ gene context.  To do this, we performed semi-quantitative RT-
PCR using primers that flank the CoTC element using RNA extracted from M12 cells 
expressing the constructs with the CoTC in both orientations (Figure 4-4, PCR 2).  
Because the CoTC in the antisense orientation should not be cleaved, the RT-PCR 
signal obtained for the CoTC(-) constructs will measure the amount of uncleaved intronic 
RNA.  If the CoTC element in the CoTC(+) constructs has been cleaved, an RT-PCR 
product will not be amplified.  Primers that amplify the region between the Cµ3 and Cµ4 
exons were used to ensure similar expression levels among the constructs (Figure 4-4, 
PCR 1).  Because the signal across the CoTC insertion site was consistently higher in 
the CoTC(-) constructs than the CoTC(+) constructs, we conclude that the CoTC 
element is being cleaved in a major portion of the transcripts.  However, because this 
activity does not affect the pA/splice expression ratio, cleavage is likely occurring after a 
commitment to one of the two competing reactions has been made. 
 
The β-globin CoTC at a proximal position does affect µ mRNA processing 
 Because the CoTC element placed at the KpnI site in the Cµ4-M1 intron did not 
affect µ alternative RNA processing choices and did not replace the activity of the NH 
pause fragment, we determined whether this element could affect µ mRNA expression 
from a location closer to the µs poly(A) signal.  We cloned the CoTC element into the 
HindIII site in the presence or absence of the NH pause element, so that the CoTC is 
either 200 bp or 50 bp, respectively, downstream of the µs poly(A) signal (Cµ/CoTC-H 
and ∆NH/CoTC-H, Figure 4-5A).  This also places the CoTC element 1475 nt upstream 
from the M1 3’ splice site.  As controls for intron size, we also inserted the rpI900 
fragment into the same locations (Cµ/rpI900-H and ∆NH/rpI900-H, Figure 4-5A).  RNA 
from M12 cells stably expressing these constructs was analyzed by S1 nuclease 
analysis (Figure 4-5B).  Compared to Cµ and ∆NH, the constructs containing the CoTC 
element had dramatically increased pA/splice mRNA ratios.  These ratios were about 3-
fold higher than the intron size controls, which indicates that the CoTC element is 
affecting µ mRNA expression at this location. The pA/splice ratios for the constructs 
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carrying the CoTC and rpI900 fragments in either the KpnI or HindIII sites are compared 
in Figure 4-5D.  It is interesting that the rpI900 fragment at either site leads to a similar 
pA/splice ratio, indicating this ratio is mainly due to the intron size.  However, while the 
construct with the CoTC element at the KpnI site expresses a pA/splice ratio similar to 
the constructs containing the rpI900 element, when the CoTC is placed in the HindIII 
site, cleavage-polyadenylation at the µs poly(A) signal is greatly enhanced.  Cµ/CoTC-H 
and ∆NH/CoTC-H expressed similar pA/splice ratios, suggesting that the CoTC element 
activity either replaced or dominated over the lost pause site activity in the ΔNH 
construct.  Thus, these experiments show that the CoTC, when placed close to the µs 
poly(A) signal does affect the pA/splice ratio. 
 The CoTC element in the β globin gene is required for transcription termination 
(Dye and Proudfoot, 2001), did not disrupt splicing of an 850 bp intron (Dye et al., 2006).  
Thus, the high pA/splice expression ratio observed when the CoTC was located near the 
µs poly(A) signal could be due to CoTC-induced early termination so that the complete 
Cµ4-M1 intron wasn’t synthesized efficiently.  It could do this either by enhancing use of 
the µs poly(A) signal or by creating cleaved ends that are entry sites for 5’-3’ 
exonucleases.  Alternatively, CoTC cleavage could interfere with Cµ4-M1 intron splicing; 
this intron is about 1 kb longer than the β globin intron that was not affected.  To 
examine the fate of RNA downstream of the CoTC element, we performed semi-
quantitative RT-PCR on total M12 RNA, using primers flanking the HindIII insertion site 
and primers across the M1 3’ splice junction in both the CoTC-containing constructs and 
the rpI900 size controls (PCR 2 and PCR 3, Figure 4-5C).  As an expression control, 
each sample was analyzed with primers in the Cµ3 and Cµ4 exons, which showed a 
similar level of expression in all four constructs (PCR 1, Figure 4-5C).  The RT-PCR 
reaction across the CoTC or rpI900 fragment insertion site clearly showed a decrease in 
RNA from the CoTC-containing constructs compared to the rpI900-containing 
constructs; the product sizes vary due to the presence or absence of the NH pause 
fragment and the difference in size between the CoTC and rpI900 fragments.  This 
difference in RNA abundance, seen with multiple dilutions of the RT reaction, suggests 
that the CoTC element is being cleaved in a substantial population of transcripts.  The 
PCR reaction detecting RNA across the 3’ M1 splice junction shows an even greater 
difference between the CoTC-containing constructs compared to the rpI900-containing 
constructs.  A signal for the CoTC-containing constructs can be seen only with the 
undiluted RT reaction, when the signal for the rpI900-containing constructs is over-
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amplified (left panel of Figure 4-5C).  This lack of a downstream RNA signal suggests 
that either the CoTC element is causing transcription to terminate before the M1 exons 
or, if this RNA is transcribed, that it is rapidly degraded.  Thus, while these results do not 
distinguish between the possible mechanisms of CoTC actions, they are fully consistent 
with previous results that demonstrated enhanced expression and termination due to the 
CoTC (West and Proudfoot, 2009).  
 
CoTC like-elements are not found in the µ gene 
 Transcription termination in the µ gene has been measured in both primary B-
lymphocytes and various lymphoid cell lines; in all cases, the transcription termination 
region was further upstream in plasma cells or stimulated B cells than in B cell lines or 
resting B cells.  It is not clear whether this change in termination pattern is due to 
changes in the use of different poly(A) signals or whether termination sequences, such 
as a CoTC element, that are more active in the plasma cells may be involved.  Thus, we 
examined the termination region of the µ gene for evidence of a CoTC element that may 
contribute to termination, possibly in a developmental stage-dependent manner.  CoTC 
elements were identified previously using a nuclear run-on hybrid selection technique 
that requires a high level of gene expression.  The cleavage activity was confirmed by 
RT-PCR reactions, using primers that spanned the predicted CoTC region (Dye and 
Proudfoot, 2001; Yuan and Tucker, 1984); PCR products were produced when the RNA 
was contiguous, but where the RNA had been cleaved, no PCR product was detected.  
We used an RT-PCR approach to screen the µ gene sequences for CoTC activity 
because expression levels are not sufficient for the hybrid selection technique.  We 
isolated nuclear RNA, to enrich for nascent RNA, from two lymphoid cell lines 
expressing the endogenous µ gene, 38C-13, a B cell line and D2, a 38C-13-derived 
hybridoma cell line (Nelson et al., 1983).  These two cell lines contain the same 
productively rearranged µ gene allele expressed in different developmental stages to 
produce different ratios of pA/splice µ mRNA.  These cell lines also have different 
transcription termination profiles by nuclear run-on assays (Kelley and Perry, 1986).  D2 
terminates downstream of the µm poly(A) signal whereas 38C-13 transcription continues 
over this region (Kelley and Perry, 1986). We designed sets of primers to amplify 
overlapping regions of the µ gene spanning about 3.7 kb of sequence downstream of the 
µs poly(A) signal (Figure 4-6A).  As a positive control for RT-PCR amplification over the 
sequences farther downstream from the µs poly(A) signal, we used an in vitro 
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transcribed RNA, containing about 600 nt upstream of the M1 exon and 1900-bp 
downstream of the µm poly(A) site (denoted as the RV RNA, Figure 4-6A).  PCR 
reaction “a” was used as the quantitation control to compare the signals between the 
38C-13 and D2 RNAs and the amount of RNA used in the RT reactions was adjusted so 
the signal intensity was similar.  This adjusted amount of RNA (1 µg of 38C-13 and 2 µg 
D2 RNA) was used in all the RT reactions.  The primers a – e were used to make cDNA 
from the two RNA samples.  The cDNA was then amplified with the primers shown 
(Figures 4-6A and 4-6B).  If a CoTC existed within the µ gene, we would expect to see 
an abrupt loss in PCR product from the RT primer that was downstream of the cleavage 
site.  If there were a CoTC element that was active selectively in one cell type, we would 
only see this abrupt loss in one RNA sample.  In fact, we observe a gradual decline in 
PCR signal as we use primers further downstream from the µs poly(A) signal; the D2 
signal declines relative to 38C-13 mostly over primers c and d (Figure 4-6C).  This is in 
good agreement with the nuclear run-on data that shows D2 termination downstream of 
the µm poly(A) signal (Kelley and Perry, 1986).  Thus, we find no evidence for a CoTC 
element that contributes to transcription termination in the µ gene. 
 
DISCUSSION 
 Transcription termination has been extensively studied in the IgM/IgD gene 
(Peterson, 1994a).  While B cells express both IgM and IgD and transcribe the entire 
locus, transcription terminates between IgM and IgD in plasma cells so that IgD is no 
longer expressed.  However, termination is not required for the RNA processing shift 
seen during B lymphocyte development because cells that express high pA/splice µ 
mRNA ratios often terminate transcription downstream of the µm poly(A) signal.  While 
there are clear differences in the transcription termination regions in B cells compared to 
plasma cells, little is known about the mechanism driving this, although changes in the 
use of the µs poly(A) signal is a possible regulatory mechanism.  Here, we explored 
whether additional sequences such as CoTC elements, located within the Cµ4-M1 intron 
or in sequences downstream of the µm poly(A) signal, are involved in transcription 
termination in B cell and plasma cells.  Using semi-quantitative RT-PCR and primers 
spanning the region 3.7 kb downstream from the Cµ4 exon, we explored whether 
nascent µ transcripts are cleaved co-transcriptionally.  This event would result in an 
abrupt loss of the PCR signal downstream of the cleavage site due to the loss of 
continuity within the nascent RNA.  However, this is not what we observed.  Instead, we 
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measured a gradual decrease in PCR signal across the region in both the B cell line 
(38C-13) and the 38C-13-derived hybridoma cell line (D2).  Termination was observed to 
occur further upstream in the D2 cells, compared to 38C-13 cells, which is consistent 
with run-on data from these cell lines (Kelley and Perry, 1986).  Therefore, we conclude 
that a CoTC element is not detectable in the µ gene.  Thus, the most likely explanation 
for transcription termination profile differences between B cells and plasma cells is that 
changes in the µs poly(A) signal use drive differential termination (Peterson, 2007).   
 Because alternative RNA processing in the µ gene relies on a balanced 
competition between a splice and a cleavage-polyadenylation reaction, subtle changes 
that affect the efficiencies of either reaction can be sensitively detected in this gene.  We 
have shown that the µ gene contains an RNA pol II pause element between 50 and 200 
nt downstream of the µs poly(A) signal that contributes to the efficient use of this poly(A) 
signal in both B cells and plasma cells (Peterson et al., 2002).  To gain a better 
understanding of the CoTC element from the β globin gene, and how it may function in 
place of the µ pause site, we placed the 800 bp CoTC element within the Cµ4-M1 intron 
at several different positions downstream of the µs poly(A) signal in the presence or 
absence of the µ pause element.  Because we knew that changes in the Cµ4-M1 intron 
size would affect the pA/splice RNA ratio, we used a series of constructs containing 
Cµ4-M1 introns of different lengths as controls for intron size.  When the CoTC element 
was inserted in the KpnI site in the active orientation (+), there was no effect on the 
pA/splice mRNA ratio over and above that expected due to the intron length, whether the 
pause site was present or not.   In this set of constructs, the distance between the CoTC 
element and the µs poly(A) signal varied from 400 nt in ∆AR/CoTC(+) to 1200 nt in 
Cµ/CoTC(+), but the distance between the CoTC element and the M1 3’ splice junction 
was a constant 500 nt.  In contrast, when the CoTC element was placed in the HindIII 
site, use of the µs poly(A) signal was greatly enhanced.  In these constructs, the 
distance between the CoTC element and the µs poly(A) signal was either 200 nt in 
Cµ/CoTC-H or 50 nt in ∆NH/CoTC -H whereas the distance between the CoTC and the 
M1 3’ splice junction is 1475 nt.  We showed that, in both locations, the CoTC element 
was causing RNA cleavage, as seen by a decrease in RT-PCR signal across the 
cleavage element compared to a similarly placed fragment without cleavage activity.  
Thus, the difference between the CoTC affecting µ processing from one intronic location 
but not another must be due to its position within the intron rather than differences in the 
fragment activity.  There are several possible explanations for this position effect, based 
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on whether the spacing between the µs poly(A) signal and CoTC or the spacing between 
the CoTC and the M1 3’ splice junction is more critical. 
 Previous studies in our lab showed that the µ pause region increased usage of 
the µs poly(A) site when it was positioned up to 100 bp downstream of its normal 
location.  However, if the pause element was moved further away, effects on the 
pA/splice RNA expression were lost (Burnside et al., 2011).  It is possible that we are 
detecting a similar strict distance effect with the CoTC at 200 nt from the µs poly(A) 
signal being able to affect the pA/splice RNA expression whereas all effects are lost at a 
position 400 nt from the µs poly(A) signal.  The basis for the limited spacing between the 
µs poly(A) signal and pause elements is not yet clear, but it suggests that a poly(A) 
signal is able to respond to pausing over a limited distance or a limited time after being 
synthesized. Although it hasn’t been systematically examined, other studies that have 
measured the effects of pause sites and CoTC elements on transcription termination 
have not described a distance effect.  Indeed, the β globin CoTC is naturally located 800 
nt from the β globin poly(A) signal although it continued to direct transcription termination 
when it was relocated to 200 nt from the poly(A) signal (Dye and Proudfoot, 2001).  A 
major difference between these assays is that in the µ gene we measure affects on 
alternative RNA processing choices of the nascent RNA, not just transcription 
termination. 
 While it is possible that the poly(A) signal – CoTC spacing affects whether the 
CoTC impacts µ RNA processing, perhaps a more likely interpretation is that the 
distance between the CoTC and the M1 3’ splice site is the more important variable that 
determines whether the CoTC affects µ mRNA processing or not.  We have previously 
explained the effect of intron size on the pA/splice RNA ratio in terms of the relative 
timing between when the µs poly(A) signal and the complete competing intron are 
synthesized; a smaller intron would allow less time for the µs poly(A) signal to be 
recognized before the splice reaction could begin to compete.  This same relative timing 
explanation may be used to interpret the position effect of the CoTC element.  In the 
constructs in which the CoTC does affect the pA/splice RNA ratio, this distance is 1475 
nt, whereas it is 500 nt in the constructs in which the CoTC has no effect.  Thus, with 
only 500 nt to be synthesized, the complete intron will be present in the nascent 
transcript sooner, so the CoTC cleavage reaction likely occurs after the nascent RNA is 
committed to one of the two competing reactions.  However, significant cleavage of the 
CoTC may occur before the M1 3’ splice junction is synthesized when this distance is 
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1475 nt and this cleavage may drive transcription termination.  Indeed, we have shown 
that there was a dramatic decrease in nascent RNA over the M1 exon in constructs 
containing the CoTC element in this location, consistent with the idea that CoTC 
cleavage is causing transcription termination so that the complete Cµ4-M1 intron was 
not synthesized efficiently to compete with the µs poly(A) signal.  This interpretation, 
based on timing, also is consistent with previous studies that introduced the β globin 
CoTC, a hammerhead ribozyme or the hepatitis δ ribozyme within the introns of the β 
globin gene.  The fast-cleaving hepatitis δ ribozyme, but not the CoTC or hammerhead 
ribozyme affected expression of β globin mRNA  (Dye et al., 2006; Fong et al., 2009).  
This suggested that RNA processing was disrupted by the faster cutting hepatitis δ 
ribozyme, which did not allow time for co-transcriptional spliceosome assembly before 
the nascent RNA was cleaved.  However, the slower cleaving CoTC element and 
hammerhead ribozyme did allow the spliceosome to commit the pre-mRNA to be spliced 
before the intron was cleaved and thus did not affect overall mRNA expression.  The 
lengths of the β globin introns are 130 and 850 nt, so the distances between the CoTC 
and the splice junctions are, in general smaller than in the µ gene.  It is possible that a 
systematic study of the distances over which effects can be detected could be used to 
estimate how rapidly these various RNA cleavage activities occur in vivo, relative to 
transcription elongation which has been measured to be about 3.8 kb min-1 (Singh and 
Padgett, 2009). 
 Previous studies on transcription termination have shown that pol II pause sites 
and CoTC elements are interchangeable to facilitate termination downstream from 
functional poly(A) signals (Gromak et al., 2006; West and Proudfoot, 2009; West et al., 
2008).   When we placed the CoTC element in the HindIII site of the Cµ4-M1 intron, 
directly downstream of the µs poly(A) signal in either the presence or absence of the µ 
pause site region, we saw a dramatic increase in the pA/splice RNA ratio, from 2.4 in the 
wild-type gene to 23-24, but we no longer detected an expression difference due to the 
pause site.  This suggests that the CoTC element activity dominates in this location.  
When other pause sites were substituted for the µ pause element, several were shown 
to be stronger because they caused an increase the pA/splice ratio compared to the 
wild-type gene, from 2.4 to 6-8 (Burnside et al., 2011).  Interestingly, transcription 
terminated further upstream in the µ genes with the stronger pause sites.  Thus, it seems 
that the pause and CoTC elements may be interchangeable for directing transcription 
termination in this µ gene context; cleavage at the CoTC element drove early termination 
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and thus a high pA/splice ratio whereas strong pause sites increased use of the µs 
poly(A) signal which then drove early termination.  An increase in the pA/splice 
expression ratio was seen in each case.  We did not determine whether the constructs 
containing the CoTC at the HindIII site were regulated between B cells and plasma cells.  
Since the pA/splice was already very extreme in B cells, we would have been able to 
measure only a 2-3-fold increase in plasma cells before we reached the limits of our 
assay.  Thus, the regulatory mechanism is likely to have been blunted due to the strong 
effect of the CoTC element. 
 While it is important to study transcription termination in simple transcription units 
to establish the connections between poly(A) signals and downstream termination 
elements, it is also valuable to consider these events in a more complex transcription 
units such as the µ gene where poly(A) site use, pause sites and transcription 
termination are developmentally regulated to alter RNA processing reactions.  A major 
conclusion from studying termination in β globin constructs was that poly(A) signal 
recognition, not cleavage, is sufficient for termination in the presence of a terminator 
such as the CoTC element (West and Proudfoot, 2008).  However, simply having a 
poly(A) signal appear in the nascent transcript can not be sufficient for termination in the 
µ gene because the µs poly(A) signal, the first of two poly(A) signals, is not recognized 
efficiently in B cells and transcription does not terminate until after the downstream µm 
poly(A) signal is used.  In plasma cells, use of the first µs poly(A) signal predominates 
and termination occurs sooner than in B cells.  Thus, there must be a mechanism to 
regulate when a poly(A) signal is recognized to trigger termination or to make the pol II 
“termination prone” and when it is skipped so transcription continues.  Because the µ 
transcription unit is both complex in structure and is regulated during B lymphocyte 
development, it is a unique model system to understand how the basic steps of 
transcription termination can be modulated to lead to different gene expression 
outcomes. 
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Figure 4-1. The CoTC element inserted in the Cµ4-M1 intron at the KpnI site does 
not affect the pA/splice mRNA expression ratio besides that expected due to 
changes in intron size.  The map of the µ gene 3’ region containing the competing µs 
poly(A) signal (µs pA) and the Cµ4-M1 splice (dotted line) is shown at the top.  The Cµ4 
exon common to both µs and µm mRNA is shown as a black box, the µs-specific exon is 
shown as a white box and the µm-specific exons M1 and M2 are shown as grey boxes.  
The previously described pol II pause site region is denoted by the small light grey box.  
Restriction sites used in cloning are shown: N, NotI; H, HindIII;, A, AccI; N, NcoI; RV, 
EcoRV; K, KpnI.  Listed below the map are the CoTC insertion constructs and the intron 
size controls (in italics), the size of each Cµ4-M1 intron, a diagram of the intron structure 
with a bar denoting deleted sequence and a triangle denoting an inserted fragment and 
the pA/splice expression ratio for each construct in M12 B cells and S194 plasma cells.  
Expression was measured by S1 nuclease analysis from cell lines stably transfected 
with each construct (see Figure 4-2); the average and standard deviation of at least 
three analyses are shown. 
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Figure 4-2. S1 nuclease analysis of the CoTC constructs and controls.  (A) Diagram 
of the end-labelled probe used to distinguish mRNA spliced at the Cµ4 5’ splice junction 
from mRNA that is cleaved and polyadenylated at the µs poly(A) signal.  (B) 
Representative S1 analyses for the constructs shown above the lanes stably expressed 
in M12 B cells; the bands for probe, mRNA that is cleaved and polyadenylated at the µs 
poly(A) signal (pA) and mRNA spliced at the Cµ4 5’ splice junction (splice) are denoted 
on the right.  (C) Representative S1 analyses for the constructs shown above the lanes 
stably expressed in S194 plasma cells; the bands for probe, mRNA that is cleaved and 
polyadenylated at the µs poly(A) signal (pA) and mRNA spliced at the Cµ4 5’ splice 
junction (splice) are denoted on the right.   
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Figure 4-3. The pA/splice expression ratio increases with increasing intron size.  
The pA/splice expression ratios, in both B cells (top panel) and plasma cells (lower 
panel), for the CoTC(+) and CoTC(-) constructs and intron size control constructs are 
plotted versus the intron size.  The data are taken from Figure 4-1. 
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Figure 4-4. The CoTC element inserted at the KpnI site is being co-
transcriptionally cleaved.  (A) Map of the µ gene 3’ region, as in Figure 4-1, showing 
the locations of the two sets of PCR primers used to analyze RNA from cells stably 
expressing µ genes containing the CoTC element.  PCR 1 (primers Cµ3T and C4B, 
Tabla 2-2) spans exons Cµ3 and Cµ4 and will detect all spliced µ mRNA.  PCR 2 (Kpn-T 
and Kpn-B, Table 2-2) spans the KpnI site that contains the CoTC(+) and CoTC(-) 
elements. (B) RT-PCR reactions using RNA from M12 B cells stably expressing the 
constructs shown above each lane.  The sizes of the marker lanes (M) and the size of 
the PCR products are shown. RT reactions in which the reverse transcriptase enzyme 
was omitted were used in the PCR reactions to ensure there was no DNA contamination 
in the RNA samples; all reactions were blank (data not shown). 
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Figure 4-5. The CoTC element inserted at the HindIII site affects expression of the 
µ gene.  (A) Map of the µ gene 3’ region, as in Figure 4-1, showing the locations of the 
three sets of PCR primers used to analyze RNA from cells stably expressing µ genes 
containing the CoTC element or the rpI900 size control fragment.  The site of fragment 
insertion is shown.  PCR 1 (primers Cµ3T and C4B, Table 2-2) spans exons Cµ3 and 
Cµ4 and will detect all spliced µ mRNA.  PCR 2 (Apa and Hind, Table 2-2) spans the 
region that contains the CoTC and rpI900 fragments.  PCR 3 (Kpn-T and M1B, Table 2-
2) spans the M1 3’ splice junction.  (B) Representative S1 analyses for the constructs 
shown above the lanes stably expressed in M12 B cells; the bands for probe, mRNA that 
is cleaved and polyadenylated at the µs poly(A) signal (pA) and mRNA spliced at the 
Cµ4 5’ splice junction (splice) are denoted on the right.  The average and standard 
deviation of at least three independent analyses are shown below each lane.  This figure 
was assembled from multiple gels.  (C) RT-PCR reactions using RNA from M12 B cells 
stably expressing the constructs shown above each lane.  The sizes of the marker lanes 
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(M) and the size of the PCR products are shown.  The panel on the left used the 
undiluted RT reaction in the PCR.  The RT reactions were diluted 1:3 for the PCR 
reactions in the right panel.  The PCR 2 products vary in size because of differences in 
the size of the CoTC and rpI900 fragments and because of the presence or absence (in 
∆NH) of the NH pause region.  (D) Graph of the pA/splice expression ratio for the 
constructs shown along the bottom, with the CoTC element or rpI900 fragment in either 
the KpnI site (black bars) or the HindIII site (white bars).  The control Cµ and ΔNH 
constructs are shown for comparison (grey bars). 
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Figure 4-6. There is no evidence for a natural CoTC element in the µ gene.  (A) Map 
of the µ gene 3’ region, as in Figure 4-1, but extending downstream to the EcoRV site, 
about 400 nt upstream of the first IgD exon.  (Cδ1, cross-hatched box).  Below in the 
hatched slim box is shown the region in vitro transcribed as the RV RNA used as a 
positive control.  Below the map is the scheme used to explore the µ gene for CoTC 
elements: the arrows marked “a” – e” are the RT primers used to make cDNA (denoted 
by dashed line) from the 38C-13 B cell line and D2 hyridoma cell line nuclear RNAs and 
the arrows connected by a solid line are the primers to make the PCR products from 
each RT reaction.  The sizes of the PCR products are indicated on the left.  (B) RT-PCR 
reactions from nuclear RNA from the 38C-13 (38C) B cell line or its hybridoma partner 
D2 or the in vitro transcribed RNA RV.  The RT primers used are shown on the left and 
correspond to the map in A and the PCR product sizes are shown on the right.  One µg 
of 38C-13 RNA and 2 µg of D2 RNA were used in each RT reaction to generate similar 
product intensity in RT-PCR “a”.  The primers used are (Table 2-2): “a”, 432AS for RT 
and CµpA-T and 432AS for PCR; “b”, 1528AS for RT and CµpA-T and 432AS for PCR; 
“c”, M2-B for RT and Kpn-T and M2-B for PCR; “d”, 469-T for RT and M2-T and 469-T 
for PCR; “e”, 473AS for RT and 469-T and 473AS for PCR. (C) The ratio of the D2 to 
38C PCR signals for each RT-PCR reaction were quantitated from two to four 
independent RT-PCR reactions and graphed. 
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CHAPTER V 
CONCLUSIONS AND STATEMENT OF SIGNIFICANCE 
 Regulation of gene expression occurs at multiple levels and it is now recognized 
that modulation of RNA processing during transcription contributes to the complexity of 
how and when a gene may be expressed.  Many human diseases have been attributed 
to misregulation of gene expression where RNA processing steps such as splicing, are 
involved.  Therefore, a better understanding of the mechanisms by which transcription is 
coupled to RNA processing could be used to develop therapeutic tools to improve 
human health.  Here, I studied two different model genes: the AFP and the µ genes to 
investigate different post-transcriptional events where a change in RNA processing is 
responsible for developmental changes in gene expression.   
 Early studies identified that AFP developmental repression by Zhx2 not only  
requires the AFP promoter (Peyton et al., 2000a) but it also involves post-transcriptional 
events (Morford, Unpublished; Vacher et al., 1992).  These data suggested that Zhx2 
may control accumulation of AFP mRNA levels by a mechanism that couples 
transcription and posttranscriptional events (Figure 1-1) (Peyton et al., 2000a).  In this 
work, we described one of the post-transcriptional steps involved in AFP developmental 
repression by Zhx2.  We observed that splicing efficiency of AFP transcripts is greatly 
reduced in the presence of Zhx2.  The global repression of AFP pre-mRNA splicing may 
explain the reduced levels of AFP expression in adult mouse liver, when Zhx2 levels are 
higher than in pre-natal stage.  Moreover, inhibition of AFP pre-mRNA splicing may also 
explain the presence of the unprocessed AFP RNA in the cytoplasm, maybe due to an 
increase in AFP pre-mRNA stability.   It is possible that the extraordinary stability of AFP 
transcripts may be attributed to the absence of exon junction complex (EJC) complexes 
that are normally deposited during splicing.  This in turn would avoid recruitment of NMD 
core effectors, allowing the unprocessed AFP transcripts escape from this surveillance 
mechanism.   
 One hypothesis about the mechanism of AFP repression by Zhx2 is that Zhx2 
may interfere with recruitment of some factors required for coupling transcription with 
RNA processing.  Because the promoter is required for AFP regulation by Zhx2, 
recruitment of these factors may occur in a promoter dependent-manner during pre-
initiation complex formation, transcription initiation and/or early transcription elongation 
(Figure 1-1, steps 1 through 3).  There are only a few reported examples where 
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uncoupling of transcription with RNA processing leads to full length unprocessed RNA.  
Two of these examples are the TNF gene in naïve T cells and the primary response 
genes (PRGs) in unstimulated macrophages (described in discussion of chapter III).  In 
the case of naïve T cells, TNF pre-mRNA splicing is blocked.  Soon after T cell 
activation, the accumulated TNF pre-mRNA is properly spliced, allowing immediate TNF 
protein expression.  The mechanism by which TNF pre-mRNA splicing is co-
transcriptionally repressed and then post-transcriptionally activated is not yet known.  In 
the case of unstimulated macrophages, the promoters of the PRGs are pre-associated 
with S5-phosphorylated RNAPII before LPS stimulation, allowing production of full-length 
pre-mRNA that is quickly degraded.  Upon LPS stimulation, p-TEFb is recruited, through 
Brd4, to phosphorylate RNAPII at S2, which results in the generation of mature RNA and 
expression of PRGs.  These examples clearly indicate that regulation of RNA processing 
can affect gene expression as a mechanism that allows quick response to stimuli.  In 
addition to p-TEFb, the Spt5 subunit of DSIF is known to be recruited during 
transcription initiation and accompanies the RNAPII during transcription elongation 
(Sims et al., 2004b).  The Spt5 subunit has been shown to participate in different RNAPII 
protein complexes and to interact with RNA processing factors such as capping 
enzymes (Lindstrom et al., 2003; Sims et al., 2004b).  Moreover, mutations in Spt5 
cause splicing defects in yeast, indicating it is required for coupling transcription and 
mRNA maturation (Lindstrom et al., 2003).  Based on all these data, factors involved in 
regulation of RNAPII CTD phosphorylation and recruitment of RNA processing factors, 
such as P-TEFb and Spt5, may be potential candidates to participate in Zhx2 regulation.  
To investigate whether the presence of Zhx2 alters the phosphorylation pattern of 
RNAPII CTD across the AFP gene, ChIP assays could be performed using antibodies 
that specifically recognize either S5- or S2-phosphorylated forms of the RNAPII CTD.  
We may expect a reduction in S2- CTD phosphorylation toward the end of the AFP gene 
if Zhx2 interferes with this process.  Recruitment of factors such as pTEF-b and Spt5 
also could be determined by ChIP assays.  Additionally, identification of Zhx2-interacting 
proteins by proteomic analysis should provide significant clues to the post-transcriptional 
steps involved in Zhx2 regulation.  Investigation of the AFP splicing repression 
mechanism by Zhx2 may increase our understanding of how gene expression could be 
regulated at early transcription steps (Figure 1-1, steps 1 through 3).  This knowledge 
may be extended to other gene systems and used as tool for amelioration of human 
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diseases.  This information also can be used to optimize cell culture systems so that 
they will reproduce the AFP similar repression levels observed in the mouse model.     
 In addition to AFP regulation, Zhx2 seems to have an important role in regulating 
expression of other genes, such as those involved in lipid metabolism.  For instance, 
BALB/cJ mice, which express low levels of Zhx2, have reduced triglyceride levels 
compared to BALB/cJ mice expressing a Zhx2 transgene in the liver, when fed with a fat 
diet (Gargalovic et al., 2010).  It was determined that reduced triglyceride levels in 
BALB/cJ mice are, in part, due to the enhanced lipoprotein lipase (Lpl)-mediated lipolysis 
and plasma clearance of triglyceride-rich plasma lipoproteins.  Since Zhx2 negatively 
impacts expression of genes involved in lipid metabolism such as Lpl, low expression of 
Zhx2 may have a protective effect on atherosclerosis and heart diseases (Gargalovic et 
al., 2010).  Additionally, the role of Zhx2 in cancer is not well established because RNA 
expression data and protein array are not consistent to each other (Hu et al., 2007; Lv et 
al., 2006).  It is possible, that subcellular localization of Zhx2 is perturbed in disease 
states.  If that were the case, studies on Zhx2 post-translational modifications may be 
performed and contribute to the overall understanding of the Zhx2 regulatory 
mechanism.   
 In contrast to the AFP gene, where regulation of gene expression occurs at an 
early step before pre-mRNA enters the splicing pathway, the µ gene developmental 
expression is due to regulated changes in cleavage/polyadenylation and splicing that 
ultimately affects transcription termination (Figure 1-1, steps 3 and 4 and Figure 1-5).  
Because CoTC elements are known to drive transcription termination in some genes 
such as the human β-globin, the human ε-globin and the mouse albumin genes, we 
decided to study whether the CoTC elements may drive transcription termination 
differences in the µ gene that occur during B cell differentiation to plasma cell.  We did 
not find evidence of a CoTC element in the Cµ4-M1 intron or further downstream of the 
M2 exon.  Therefore, we utilized the complex gene structure of the µ gene to better 
understanding the effect of cleaving the pre-mRNA within the Cµ4-M1 intron on the µ 
gene RNA processing.  We did show that a cleavage induced by the β-globin CoTC 
element can affect the pA/splice mRNA ratio in certain intronic positions.  Inserting the β-
globin CoTC within the Cµ4-M1 intron induced cleavage of the RNA transcript 
independent of where it was located, but only insertion of the CoTC element 
downstream of the µspA dramatically affected the balance of the two competing 
reactions to enhance usage of the µspA.  We explain this positional effect based on 
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timing (Figure 5-1).  The presence of the CoTC toward the end of the Cµ4-M1 intron 
(KpnI site) may allow enough time for proper co-transcriptional spliceosome assembly 
before cleavage occurs and thus splicing could compete with cleavage/polyadenylation 
at µspA (Figure 5-1A).  However, when the CoTC element is present directly 
downstream of the µspA, cleavage may occur before spliceosome assembly so that 
splicing can not outcompete cleavage/polyadenylation at µspA (Figure 5-1B).  In 
addition, the CoTC element drives early transcription termination.  Several studies have 
addressed the effect on splicing by inducing cleavage within an intron (Dye et al., 2006; 
Fong et al., 2009).  It was observed that a fast-cutting ribozyme such as the δ ribozyme 
impairs splicing, while insertion of a slower-cutting ribozyme or the β-globin CoTC 
element did not have the same effect.  It was concluded that splicing is affected when 
cleavage within the intron is fast enough to interfere with the co-transcriptional 
spliceosome assembly (Fong et al., 2009).  Here, we extended these findings using the 
µ gene where a splicing reaction is in competition with a cleavage/polyadenylation 
reaction.  We observed that indeed, the CoTC element could affect splicing when 
inserted close to the 5’ splice site and in this case, it enhances the cleavage at the µspA 
which results in higher µs mRNA production, rather than leads to an unproductive 
transcript.  These results can also support evidence about microRNA (miRNA) 
processing.  MiRNAs are noncoding RNA species of ∼22 nt that are involved in post-
transcriptional gene silencing (Kim and Kim, 2007).  These RNAs are encoded not only 
within intergenic regions but also within introns of protein-coding transcrips.  MiRNA 
processing includes cleavage by Drosha to release ∼70 nt pre-miRNAs that are then 
processed by Dicer to generate mature ∼22 nt miRNAs.  This raises the question of how 
intronic miRNA are processed without disrupting proper RNA processing of mRNAs (Kim 
and Kim, 2007).  Our studies together with those mentioned above support the idea that 
Drosha may excise intronic miRNA after splicing is committed (Fong et al., 2009; Kim 
and Kim, 2007).   
 Better understanding of µ gene RNA processing regulation could improve our 
knowledge of the cis- and trans-acting factors involved in alternative RNA processing 
and the mechanism involved in that regulation.  The µ gene with its complex gene 
structure can serve as a model for studying splicing, cleavage/polyadenylation and 
transcription termination. The information gained about the µ gene regulatory 
mechanisms could be extended to other gene systems to modulate gene expression 
under pathological conditions.  
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Figure 5-1. Model of the β-globin CoTC element insertion effect on µ gene RNA 
processing. (A) Insertion of CoTC element at the KpnI site with in the Cµ4-M1 intron. 
(B) Insertion of CoTC element at the HindIII site with in the Cµ4-M1 intron. 
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